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ABSTRACT 
 Attention-deficit/hyperactivity disorder (ADHD) is highly comorbid with 
substance use disorders, particularly cocaine. Preclinical studies using the well-validated 
Spontaneously Hypertensive Rat (SHR) model of ADHD suggest that adolescent 
treatment with the stimulant methylphenidate increases cocaine abuse risk in adulthood, 
highlighting the need to identify alternative medications for teenagers with ADHD. 
Experiments 1-4 tested the hypothesis that atomoxetine, a non-stimulant that improves 
prefrontal cortex functioning in adolescent SHR, would not increase cocaine abuse risk.  
The speed to acquire cocaine self-administration, the efficacy and motivating influence of 
cocaine reinforcement, and reactivity to cocaine cues in adulthood following 
discontinuation of adolescent atomoxetine treatment were examined in male SHR and 
two genetic control strains: inbred Wistar-Kyoto (WKY) and outbred Wistar (WIS). 
Because atomoxetine is not always as clinically efficacious as methylphenidate, 
Experiments 5-9 tested the hypothesis that an alternative stimulant, d-amphetamine, 
would improve cognitive performance in adolescent SHR during a strategy set-shifting 
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task and not increase cocaine abuse risk in adult SHR after adolescent d-amphetamine 
was discontinued. Across experiments, adult SHR acquired cocaine self-administration 
faster than control strains and also were more sensitive to cocaine’s reinforcing and 
motivating influence and more reactive to cocaine cues. As hypothesized, adolescent 
atomoxetine did not increase any measure of cocaine abuse risk in adult SHR and 
modestly reduced SHR’s reactivity to cocaine cues. In WKY control, however, 
adolescent atomoxetine accelerated acquisition of cocaine self-administration. d-
Amphetamine improved set-shifting deficits in adolescent SHR, demonstrating pro-
cognitive effects as hypothesized. When self-administration was acquired, cocaine intake 
was lower in adult SHR that received adolescent d-amphetamine compared to vehicle-
treated SHR, consistent with the hypothesis. Adolescent d-amphetamine slowed 
acquisition and reduced the efficacy and motivating influence of cocaine reinforcement in 
WIS control, but accelerated acquisition in WKY control. Collectively, these results 
highlight the heuristic value of SHR in evaluating comorbid ADHD and cocaine abuse 
risk, and suggest that atomoxetine and d-amphetamine may be safer medications than 
methylphenidate for teenagers with ADHD. However, findings in control strains 
emphasize the need for accurate ADHD diagnosis, as the long-term consequences of 
treatment could be favorable (d-amphetamine in WIS) or unfavorable (atomoxetine and 
d-amphetamine in WKY) in misdiagnosed individuals.    
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CHAPTER ONE. 
 
 General Introduction 
 
 Attention-deficit/hyperactivity disorder (ADHD) is a widely prevalent 
neurodevelopmental disorder that affects 8-12% of children and adults worldwide, up to 
~78% of whom may experience symptoms that persist in adulthood (Biederman et al, 
2010; Visser et al, 2014). In the United States, ADHD diagnoses increased by 42% from 
2003 to 2011, with rates escalating fastest among teenage boys aged 14 to 17 (Schwarz & 
Cohen, 2013; Visser et al, 2014). Adolescents and adults with ADHD are at a high risk of 
drug abuse. Comorbidity estimates of ADHD and substance use disorder (SUD) range 
from 9.5% up to 58%, depending on the sample (Sizoo et al, 2010; Steinhausen & 
Bisgaard, 2014). Moreover, ADHD is a significant predictor of SUD (Wilens et al, 2011), 
and is associated with earlier onset and increased severity of SUD, as well as greater 
functional impairments resulting from drug use (de los Cobos et al, 2011; Kousha et al, 
2012). Although nicotine, alcohol, and cannabis represent the most frequently abused 
drugs by individuals with ADHD (Faraone et al, 2007), ADHD patients are also more 
likely than those without ADHD to escalate their use to include other illicit drugs, 
particularly cocaine (Biederman et al, 2006). The lifetime prevalence of cocaine use 
disorder in individuals with ADHD is 23%, more than double the prevalence of cocaine 
use disorder observed in the general population, which is 10.8% (Lambert, 2005). 
Consistent with these rates, meta-analysis has shown that children with ADHD are twice 
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as likely to abuse cocaine or to become cocaine dependent in adulthood, compared to 
children without ADHD (Lee et al, 2011). ADHD and cocaine abuse share several 
behavioral and neurological features, which may contribute to high comorbidity of these 
disorders.  
 
ADHD and Cocaine Abuse  
 The core characteristics of ADHD include hyperactivity, impulsivity, and 
inattention (American Psychiatric Association, 2013). Other robust features of ADHD 
include deficits in inhibitory control, working memory, and behavioral flexibility, as well 
as elevated sensitivity to novelty (Barkley, 1997; Rapport et al, 2008; Tengelbeckers et 
al, 2015). Drug dependence is defined by a loss of control over drug consumption and 
continued drug use despite negative consequences (American Psychiatric Association, 
2013). Consistent with this definition, cocaine-abusing individuals exhibit impulsivity 
and deficits in sustained attention, working memory, and inhibitory control (Burgess et 
al, 2010; Colzato et al, 2009; Hester & Garavan, 2004; Potvin et al, 2014; Vonmoos et al, 
2013). However, it remains unclear whether these deficits contribute to the development 
of cocaine dependence, or whether they are a result of chronic drug use.  
 Several overlapping neural substrates underlie the behavioral features that ADHD 
and cocaine dependent individuals have in common. For example, during inhibitory 
control tasks, individuals with ADHD show reduced activation in the right inferior frontal 
gyrus (IFG), as well as in medial prefrontal and orbitofrontal cortices (mPFC and OFC, 
respectively), compared to individuals without ADHD (Booth et al, 2005; Cubillo et al, 
  
3	  
2011; Depue et al, 2010; Rubia et al, 2005). Cocaine users similarly fail to show 
activation in mPFC or dorsolateral prefrontal cortex (DLPFC) during inhibitory control 
tasks, which is typically observed in non-drug using controls (Hester & Garavan, 2004). 
Moreover, during reward-based tasks, increased activation in the OFC is observed both in 
individuals with ADHD and in cocaine using subjects, compared to controls (Bolla et al, 
2003; von Rhein et al, 2015).  
 Dysfunction in the dopamine neurotransmitter system may underlie many of the 
behavioral and neurobiological features that individuals with ADHD and cocaine 
dependent individuals have in common. For example, individuals with ADHD exhibit 
decreased dopamine D2 receptor availability (Volkow et al, 2010), and have specific 
polymorphisms in the dopamine transporter (DAT) -1 gene (Faraone et al, 2005; Fusar-
Poli et al, 2012). These polymorphisms likely contribute to the abnormal DAT function 
and increased DAT levels observed in the striatum of ADHD patients (Fusar-Poli et al, 
2012; Hesse et al, 2009). Notably, the striatum is a region in which the DAT-1 gene is 
predominantly expressed in the brain (Durston et al, 2005), and plays a critical role in 
motivation and reward-associated learning. Cocaine users similarly exhibit decreased D2 
receptor availability and polymorphisms in the DAT-1 gene, in some of the same introns 
as those observed in ADHD (Asherson et al, 2007; Franke et al, 2010; Guindalini et al, 
2006; Hoogman et al, 2012). Moreover, DAT-1 polymorphisms also likely contribute to 
abnormal DAT function in the striatum of cocaine users (Mash et al, 2002; Volkow et al, 
2010). Interestingly, individuals with ADHD who receive stimulant medications for their 
symptoms exhibit increased DAT levels compared to medication-naïve ADHD patients 
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(Fusar-Poli et al, 2012), and cocaine abuse is associated with increased DAT function in 
the striatum (Mash et al, 2002). If long-term stimulant medication exacerbates DAT 
dysfunction in ADHD, this may also contribute to increased cocaine abuse risk in these 
individuals. The neural mechanisms associated with sensitization, an important 
consequence of repeated stimulant exposure, support this possibility.   
 
Stimulant Drugs and Sensitization 
 Acutely, all drugs of abuse activate the mesocorticolimbic dopamine “reward” 
pathway, either directly or indirectly. The mesocorticolimbic pathway involves the 
ventral tegmental area (VTA), from which dopaminergic axons project to the nucleus 
accumbens and PFC. Drugs of abuse are thought to “hijack” this pathway by augmenting 
dopamine signaling (Buchta & Riegel, 2015). For example, cocaine inhibits monoamine 
transporters, serving to increase extracellular dopamine and other monoamines. Drug-
seeking and drug-taking behaviors are thus reinforced in place of the pursuit of natural 
rewards, such as food, which do not increase extracellular dopamine to the same 
magnitude (Buchta & Riegel, 2015). Cocaine use also affects other brain regions, many 
of which have reciprocal connections with the nucleus accumbens and VTA. These 
include the striatum, amygdala, hippocampus, and cingulate cortex (Steketee & Kalivas, 
2011), as well as specific subregions of the PFC, such as mPFC/DLPFC and OFC, as 
reviewed above (Bolla et al, 2003; Booth et al, 2005; Hester & Garavan, 2004). 
 Rather than causing tolerance, long-term or repeated administration of stimulant 
drugs may induce sensitization. Sensitization is broadly defined as enhanced 
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responsiveness to the drugs’ effects, both with respect to behavior and within the brain. 
For example, it is well established in rodents that repeated administration of low doses of 
cocaine increases locomotor activity (see Steketee & Kalivas, 2011, for review). The 
reinforcing value of the drug, as well as the salience of drug-related cues, can also 
increase with repeated stimulant use (Robinson & Berridge, 1993). A number of neural 
changes are thought to underlie sensitization to drugs and drug-related cues. These 
include increases in dopamine and glutamate release in the VTA, nucleus accumbens, and 
mPFC, in response to stimulant administration (Steketee & Kalivas, 2011). In particular, 
increased activation of D1 receptors in these regions appears to be critical to the 
development of sensitization (Steketee & Kalivas, 2011). For example, D1 receptor 
responsivity in the nucleus accumbens increases with repeated cocaine administration 
(Henry & White, 1991). Moreover, infusion of D1 agonists into the nucleus accumbens 
or VTA augments sensitization to cocaine (De Vries et al, 1998; Pierce et al, 1996). In 
contrast, D1 antagonists in the VTA block the development of sensitization (Vezina, 
1996). Similarly, antagonists of dopamine D1 and glutamate receptors in mPFC block the 
formation of sensitization to stimulant drugs (Li et al, 1999; Ramos et al, 2005).  
 Sensitization has also been linked to other synaptic changes in the 
mesocorticolimbic dopamine pathway. For example, one measure of excitatory synaptic 
strength is the ratio of AMPA to NMDA glutamate receptors (AMPAR/NMDAR). In the 
VTA, neurons showed elevated AMPAR/NMDAR ratios for up to 1 week following a 
single cocaine injection, and for up to 3 months following chronic cocaine self-
administration (Chen et al, 2008; Lüscher & Malenka, 2011). Importantly, changes in 
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VTA plasticity following cocaine administration are dependent on D1 receptor activation 
(Schilström et al, 2006; Steketee & Kalivas, 2011). In contrast to the VTA, excitatory 
synaptic strength in the nucleus accumbens may be reduced by repeated cocaine 
administration. Decreased AMPAR/NMDAR ratios are observed in medium spiny 
neurons for up to 14 days after the last cocaine exposure (Lüscher & Malenka, 2011; 
Kourrich et al, 2007; Thomas et al, 2001).  
 One additional neurochemical change important to sensitization occurs at 
monoamine transporters. For example, DAT inhibition is necessary for cocaine-induced 
changes in nucleus accumbens plasticity, as well as cocaine-induced locomotor 
sensitization (Martin et al, 2011). Interestingly, continuous access to cocaine reduces 
cocaine’s ability to block DAT (Calipari et al, 2013). In contrast, intermittent access to 
cocaine, which may be more representative of “real-world” cocaine use, increases 
cocaine’s potency at DAT (Calipari et al, 2013). Importantly, increases in DAT are 
associated with ADHD, and may be a consequence of stimulant medication (Fusar-Poli et 
al, 2012; Hesse et al, 2009). Based on this understanding of sensitization, concern has 
been raised regarding the treatment of ADHD with stimulant drugs.  
 
Changes in Cocaine Abuse Risk following Treatment for ADHD  
 In the United States, two-thirds of individuals diagnosed with ADHD receive a 
stimulant medication for their symptoms (Schwarz & Cohen, 2013). The most commonly 
prescribed stimulant medication is methylphenidate (Ritalin®; Castle et al, 2007; Raman 
et al, 2015; Visser et al, 2014). Methylphenidate is considered the first-line treatment for 
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ADHD (MTA Cooperative Group, 1999), and can result in up to 50% reduction in 
ADHD symptoms (Buitelaar et al, 2011; Scahill et al, 2004). Methylphenidate acts by 
inhibiting reuptake at DAT and at norepinephrine transporters (NET), resulting in 
increased extracellular concentrations of dopamine and norepinephrine (Gatley et al, 
1996; Wilens, 2006). Regionally, in boys with ADHD methylphenidate increases right 
IFG activity, and normalizes hypoactivation in the ventrolateral PFC (VLPFC), which is 
associated with improved inhibitory control compared to placebo administration (Cubillo 
et al, 2012; Rubia et al, 2014). Increased stimulation at dopamine D1 and alpha2A 
noradrenergic receptors is thought to underlie methylphenidate’s acute cognitive-
enhancing effects (Arnsten & Dudley 2005; Gamo et al 2010).  
 Although methylphenidate may be efficacious in improving ADHD symptoms in 
the short-term, controversy remains regarding chronic treatment (Sibley et al, 2014). 
After moderate- and long-term follow up, increases in methylphenidate use were 
associated with increased school grade repetition and deteriorating parental relationships 
for boys with ADHD, and with unhappiness, depression, lower math scores, reduced 
higher education attendance, as well as deteriorating parental relationships for girls with 
ADHD (Currie et al, 2014; NBER, 2015). Further, as suggested above, controversy has 
risen regarding the relationship between methylphenidate treatment and increased risk of 
SUD in adulthood, beyond the risk conveyed by having ADHD alone. An early meta-
analysis reported that stimulant treatment is protective against SUD (Wilens et al, 2003). 
However, the studies that were examined in the analysis failed to consider whether 
stimulant treatment was initiated in childhood vs. adolescence, or was ongoing vs. 
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discontinued at the time of assessment. Because substance use may be a form of self-
medication for individuals with ADHD (Gudjonsson et al, 2012), ongoing 
methylphenidate treatment may compromise detection of increased cocaine abuse risk 
(Baskin et al, 2015; Schenk & Izenwasser, 2002). Moreover, clinical studies also often 
fail to distinguish between different types of stimulant medication, which may have 
different mechanisms of action and potentially different long-term behavioral effects, a 
possibility that is explored in Chapter Three. Finally, many studies in human subjects 
typically employ a limited follow-up period in adult participants. Because cocaine use 
generally develops later in life (Degenhardt et al, 2008), participants evaluated in their 
late teens and early twenties may not have surpassed the risk period for cocaine use 
(Humphreys et al, 2013).   
 Despite these limitations, current consensus is that initiation of stimulant 
treatment in childhood neither protects against, nor promotes, the risk of SUD 
(Humphreys et al, 2013; Molina et al, 2013; Volkow et al, 2008). However, controversy 
remains regarding initiation of stimulant medication during adolescence and the long-
term consequences for SUD. When age of treatment onset is analyzed, evidence emerges 
indicating that the later in childhood that treatment is initiated, the greater the increase in 
the risk of developing SUD (Dalsgaard et al, 2014; Lambert et al, 1998; Manuzza et al, 
2008; Steinhausen & Bisgaard, 2014). Several factors have been suggested to mediate 
this link between the age at which stimulant treatment is initiated and later substance 
abuse, including the number of active ADHD symptoms, the duration of untreated 
symptoms, and the development of antisocial personality disorder. However, the 
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cumulative duration of stimulant treatment is not associated with development of SUD 
(Dalsgaard et al, 2014), and conduct problems, which are precursors to antisocial 
personality disorder, do not differ between patients who initiate ADHD medication in 
childhood vs. adolescence (Mannuzza et al, 2008; Upadhyaya et al, 2005). These findings 
suggest that the duration of untreated symptoms and antisocial personality disorder 
cannot fully account for increased SUD following adolescent stimulant treatment. 
Importantly, adolescence is a distinct developmental period characterized by elevated 
plasticity in the mesocorticolimbic system. The unique neurological changes occurring 
during adolescence may therefore render the brain more susceptible to the sensitizing 
effects of stimulant drugs. 
 
Adolescence: A Sensitive Period 
 Adolescence may be a vulnerable period when stimulants, which directly 
influence monoaminergic activity in the mesocorticolimbic system, have unique effects 
on reward responsivity (Andersen, 2005). Regionally, healthy teenagers exhibit 
hypoactivity in the some of the same brain regions that are dysfunctional in both 
individuals with ADHD and cocaine abusers, including the mPFC/DLPFC and OFC 
(Bolla et al, 2003; Booth et al, 2005; Hester & Garavan, 2004; Stanger et al, 2013). 
Interestingly, hypoactivation in mPFC/DLPFC is also associated with impulsivity in 
teenagers (Stanger et al, 2013).  
 The neural changes that occur during adolescence may interact synergistically 
with those involved in sensitization to stimulant drugs, particularly in individuals with 
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ADHD. For example, during adolescence, D1 receptors are overproduced in the mPFC, 
particularly on glutamatergic neurons that project to the nucleus accumbens (Andersen et 
al, 2001; Brenhouse et al, 2008; Stanis & Andersen, 2014). Altered D1 receptor activity 
is also associated with some of the behavioral characteristics of adolescence, such as 
impulsivity and novelty seeking, which are also notable in ADHD and drug users (Potvin 
et al, 2014; Stanis & Andersen, 2014, Tengelbeckers et al, 2015; Vonmoos et al, 2013). 
Moreover, as reviewed above, D1 receptors in the nucleus accumbens are critical for 
stimulant sensitization (De Vries et al, 1998; Henry & White, 1991; Pierce et al, 1996; 
Steketee & Kalivas, 2011).  
 Monoamine transporters are also differentially expressed throughout 
development. In the frontal cortex, serotonin transporter (SERT) levels increase steadily 
from early adolescence through old age (Moll et al, 2000). NET density in frontal cortex 
decreases from early to late adolescence, but thereafter remains stable throughout 
adulthood (Moll et al, 2000). In contrast, DAT density increases in the striatum from 
early adolescence until peaking in late adolescence. Thereafter, striatal DAT density 
declines throughout adulthood (Moll et al, 2000). As reviewed above, DAT is a critical 
mediator of sensitization to stimulants in reward-associated regions (Martin et al, 2011). 
DAT is also elevated in individuals with ADHD and those abusing cocaine (Fusar-Poli et 
al, 2012; Hesse et al, 2009; Mash et al, 2002; Moll et al, 2000). Chronic exposure to 
methylphenidate as a treatment for ADHD during the teenage years, when D1 receptor 
and DAT levels are at their highest, may therefore result in greater vulnerability to 
sensitization and later cocaine abuse risk, compared to juveniles or adults. It is worth 
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noting that clinically relevant doses of methylphenidate do not induce locomotor 
sensitization (Kuczenksi & Segal, 2002). However, this does not translate to a lack of 
neurochemical effects or consequences for cocaine abuse risk. Rather, the neurochemical 
adaptations associated with adolescent methylphenidate treatment closely resemble those 
associated with stimulant sensitization. For example, chronic methylphenidate exposure 
increases dendritic spine density in the nucleus accumbens, particularly on D1-receptor 
expressing medium spiny neurons, and also may increase DAT levels in striatum or PFC 
(Fusar-Poli et al, 2012; Kim et al, 2009; Somkuwar et al, 2013b).  
 Despite these observations, there are currently no well-controlled studies on 
methylphenidate initiation after age 13 in individuals with ADHD. Evaluation of long-
term effects of adolescent methylphenidate on SUD risk in human populations has been 
complicated by difficulty in controlling certain variables across patients, such as the 
presence of conduct disorder, the precise age at which treatment was initiated, and the 
prescription of mixed medications, which may convey varying degrees of risk 
(Steinhausen & Bisgaard, 2014). Fortunately, preclinical animal models using carefully 
controlled experimental conditions can help address these clinically relevant questions in 
ADHD. 
 
 The Spontaneously Hypertensive Rat Model of ADHD 
 Preclinical models can begin to address important gaps in the clinical literature 
regarding the long-term consequences of adolescent ADHD medication for SUD and 
particularly cocaine abuse risk. However, studies in outbred animals have revealed 
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somewhat conflicting findings. For example, methylphenidate exposure during the rat 
juvenile period had no effect on cocaine conditioned place preference, but increased 
cocaine intake during self-administration in adulthood (Crawford et al, 2011), in contrast 
to observations in the clinical literature. Conversely, exposure to methylphenidate during 
the rat adolescent period reduced cocaine conditioned place preference in adulthood 
(Adriani et al, 2006; Andersen et al, 2001; Carlezon et al, 2003), and also decreased high-
dose cocaine self-administration (1 mg/kg/infusion, Thanos et al, 2007), but increased 
low-dose cocaine self-administration (0.075 mg/kg/infusion, Brandon et al, 2001). These 
apparently conflicting findings emphasize the need to study cocaine abuse risk in an 
appropriate animal model, which exhibits a behavioral and neurobiological profile that 
mirrors observations in individuals with ADHD. Outbred animals, in contrast, are 
presumably more representative of the general population.  
 The Spontaneously Hypertensive Rat (SHR) is the most well-validated and 
frequently studied animal model of ADHD (Kantak et al, 2008; Russell et al, 2005; 
Sagvolden et al, 2005). SHR exhibit core symptoms of ADHD, including hyperactivity, 
impulsivity, and inattention (Adriani et al, 2003; Bayless et al, 2015; Hill et al, 2012; 
Sagvolden, 2000), inhibitory control and working memory deficits (Bayless et al, 2015; 
Kantak et al, 2008), as well as poor behavioral flexibility (Harvey et al, 2013), and 
increased novelty seeking (dela Peña et al, 2015). Cognitive dysfunction in SHR is most 
evident under difficult task conditions, such as when a delay is imposed between a 
correct response and delivery of reward, consistent with observations in humans with 
ADHD (Aase & Sagvolden, 2006; Harvey et al, 2013; Martinussen et al, 2005). 
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Moreover, these deficits are unrelated to hypertension, as SHR show ADHD-like 
symptoms even at pre-hypertensive ages (Russell et al, 2005; Watanabe et al, 1997), and 
anti-hypertensive treatment does not improve cognitive functioning in the SHR (Wyss et 
al, 2003). The Wistar-Kyoto rat (WKY), which is the progenitor strain of the SHR, does 
not exhibit hyperactivity, impulsivity, or hypertension, and is frequently used as an 
inbred control strain (Russell et al, 2005), while the Wistar rat (WIS), a common ancestor 
to both SHR and WKY, is used as an outbred control strain (dela Peña et al, 2012). 
Concurrent evaluation of these three strains is necessary to control for the genetic 
homogeneity of the SHR (using the WKY), while still representing the genetic 
heterogeneity of the general population (using the WIS).   
 Importantly, clinically relevant doses of ADHD medications alleviate ADHD-
related symptoms in SHR. For example, in adolescent SHR, methylphenidate treatment 
improved the speed to learn visual cue discrimination and initial set formation, and 
reduced perseverative and regressive errors in attentional and strategy set shifting tasks, 
which are analogous to the Wisconsin Card Sorting Task in humans (Cao et al, 2012; 
Floresco et al, 2008, Harvey et al, 2011; 2013). The predictive validity of the SHR likely 
relates to the genetic and neurochemical similarities that SHR share with ADHD patients. 
For example, both individuals with ADHD and the SHR exhibit altered frontostriatal 
connectivity (Cubillo et al, 2012; Rubia, 2011; Warton et al, 2009), and elevated 
glutamate and dopamine release in PFC and striatum (Courvoisie et al, 2004; MacMaster 
et al, 2003; Miller et al, 2014). Moreover, as reviewed above, ADHD is associated with 
specific polymorphisms in the DAT-1 gene, (Faraone et al, 2005; Fusar-Poli et al, 2012), 
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and variation in the DAT-1 gene has also been observed in the SHR, which is 94% 
homologous to the human DAT-1 gene (Mill et al, 2005). SHR also exhibit increased 
binding and expression of DAT in the striatum and substantia nigra/VTA (Roessner et al, 
2010; Watanabe et al, 1997), consistent with observations in human patients (Faraone et 
al, 2005; Fusar-Poli et al, 2012).   
  In addition to exhibiting cognitive and neurochemical deficits associated with 
ADHD, the SHR is also a compelling model for comorbid ADHD and cocaine abuse. In 
cocaine self-administration studies, SHR acquire lever pressing for cocaine faster, earn 
more cocaine infusions, are more sensitive to the reinforcing value of cocaine, and work 
harder to earn cocaine reinforcement than both WKY and WIS control strains (Harvey et 
al, 2011; Jordan et al, 2014; Somkuwar et al, 2013a). These findings indicate that the 
SHR may also be useful in evaluating the long-term consequences of adolescent ADHD 
medication on cocaine abuse risk in adulthood. Consistent with clinical studies 
(Mannuzza et al, 2008), adolescent treatment with a clinically relevant dose of oral 
methylphenidate further enhanced the speed to acquire cocaine self-administration, and 
further increased the efficacy and motivating influence of cocaine reinforcement in SHR, 
but did not increase self-administration behaviors in WKY or WIS control strains (Baskin 
et al, 2015; Harvey et al, 2011; Jordan et al, 2014). The same adolescent methylphenidate 
treatment regimen was found to increase DAT function in the mPFC of adult SHR, 
relative to untreated SHR and methylphenidate-treated WKY and WIS (Somkuwar et al, 
2013b). Although cortical DAT function in ADHD has not been reported, these findings 
in the SHR model are consistent with observations in humans, as individuals with ADHD 
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who are treated with stimulant medications exhibit increased DAT levels compared to 
medication-naïve patients (Fusar-Poli et al, 2012). An increase in DAT function in mPFC 
may lead to faster clearance of dopamine and lower basal dopaminergic tone in 
mesocortical neurons (Zahniser & Sorkin, 2004). When cocaine is self-administered 
under these conditions, post-synaptic responses to phasically released dopamine would 
therefore be increased (Grace, 2001), leading to a greater reinforcing effect of cocaine in 
adult SHR that were treated with methylphenidate during adolescence. Importantly, these 
observations were not necessarily a result of discontinuing methylphenidate in adulthood. 
Adult SHR continued to show elevated motivation to self-administer cocaine when 
methylphenidate treatment was continued, as long as methylphenidate was administered 
after cocaine self-administration sessions (Baskin et al, 2015). However, when 
methylphenidate treatment was administered 1 hour prior to cocaine self-administration 
sessions, SHR did not show increases in cocaine intake compared to vehicle-treated SHR 
(Baskin et al, 2015). Methylphenidate pretreatment may block cocaine’s ability to bind to 
DAT, by competing at the same binding site (Berglund et al, 2013; Volkow et al, 1995). 
Therefore, administration of methylphenidate prior to cocaine self-administration 
sessions may mask elevated cocaine abuse risk in adult SHR (Baskin et al, 2015; Schenk 
& Izenwasser, 2002). These observations suggest that if an individual with ADHD does 
not properly adhere to their methylphenidate treatment regimen, they may remain at 
increased risk of cocaine abuse, if cocaine is sampled (Baskin et al, 2015). 
 Taken together, findings in SHR support human studies suggesting that initiation 
of methylphenidate treatment in adolescence increases cocaine abuse risk in adulthood 
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(Dalsgaard et al, 2014; Lambert et al, 1998; Manuzza et al, 2008; Somkuwar et al, 2013b; 
Steinhausen & Bisgaard, 2014). The effects of adolescent methylphenidate treatment may 
be due to sensitization-related neurochemical changes induced by methylphenidate that 
persist even after treatment is discontinued. It is therefore critical to identify alternative 
treatments for newly diagnosed teenagers with ADHD, who may be at increased risk for 
substance abuse later in life if treated with methylphenidate.  
 
 
CHAPTER TWO.   
 
Aim 1: Treatment with a Non-Stimulant ADHD Medication During Adolescence 
and Cocaine Abuse Risk and Cocaine Cue Reactivity in Adulthood 
 
Introduction 
 One potential alternative to methylphenidate treatment for adolescents with 
ADHD is the non-stimulant drug, atomoxetine (Strattera®). Unlike methylphenidate, 
atomoxetine has a very low affinity for DAT (Heal et al, 2008). Atomoxetine acts by 
selectively inhibiting reuptake at NET, resulting in increased extracellular concentrations 
of norepinephrine (Byamster et al, 2002). In addition, because dopamine uptake in the 
PFC is primarily by NET (Morón et al, 2002), atomoxetine increases extracellular 
concentrations of both norepinephrine and dopamine in this region (Bymaster et al, 
2002). However, because atomoxetine does not increase dopamine transmission in the 
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striatum, it has low abuse potential, unlike methylphenidate (Wilens, 2006). Atomoxetine 
has moderately comparable efficacy to methylphenidate in relieving ADHD symptoms 
(Kratochvil et al, 2002), but may be more efficacious in certain subpopulations of 
ADHD, such as those with comorbid anxiety, in whom methylphenidate may worsen 
certain symptoms (Adler et al, 2009; Geller et al, 2007; Goez et al, 2007). Regionally, 
atomoxetine increases activation in the right IFG of healthy volunteers (Chamberlain et 
al, 2009), and normalizes DLPFC hypoactivation in boys with ADHD (Cubillo et al, 
2014). However, atomoxetine may not be as efficacious as methylphenidate in mediating 
VLPFC function or in improving performance on discrimination tasks (Cubillo et al, 
2014; Smith et al, 2013). Similar to methylphenidate, increased stimulation at dopamine 
D1 and alpha2A noradrenergic receptors is thought to underlie atomoxetine’s cognitive-
enhancing effects (Arnsten & Pliszla, 2011). It is worth noting here that guanfacine 
(Intuiv®) is another non-stimulant medication for ADHD, which acts as an agonist at 
alpha2a noradrenergic receptors (Nakagawa et al, 1982; Wilens, 2006). However, 
guanfacine is more often prescribed as an adjunct therapy to stimulant medications, and 
has limited efficacy in adolescents with ADHD (Sibley et al, 2011). Atomoxetine is 
therefore the focus of Aim 1.  
 In adolescent SHR, a pharmacologically relevant dose of atomoxetine improves 
behavioral flexibility during the set shift phase of the strategy set shifting task (Harvey et 
al, 2013). Behavioral flexibility during the set shift phase is a process that is dependent 
on mPFC function (Floresco et al, 2008). Atomoxetine also progressively and dose-
dependently reduces hyperactivity in young adult SHR over the course of 21 days of 
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treatment (Moon et al, 2014). Unlike methylphenidate, adolescent treatment with 
atomoxetine does not alter DAT function in mPFC in adulthood, but rather decreases 
DAT function and cell surface distribution in the OFC of adult SHR (Somkuwar et al, 
2013a). Thus, atomoxetine-induced improvement in set shifting, a mPFC-mediated 
process, cannot be explained by a change in DAT function in SHR. A decrease in NET 
function in mPFC of SHR could explain such an improvement, as previous research in 
outbred rats has shown improvement in set shifting performance after activation of 
alpha1 noradrenergic receptors in mPFC (Lapiz & Morilak, 2006) and impairment after 
selective noradrenergic lesions in mPFC (McGaughy et al, 2008). Interestingly, ADHD is 
associated with variations in the NET allele, which are related to externalizing symptoms 
such as impulsivity (Hohmann et al, 2015). However, additional work is needed to 
determine the effects of adolescent atomoxetine treatment on mPFC NET function in 
SHR.  
The decrease in DAT function and cell surface distribution in the OFC of adult 
SHR may play a role in potentially protective effects of adolescent atomoxetine on 
cocaine abuse risk (Somkuwar et al, 2013a). Importantly, dopamine transmission in the 
OFC is associated with cocaine seeking (Di Pietro et al, 2008), and transient inactivation 
of the OFC may reduce the motivation to self-administer cocaine and alter cocaine’s 
reinforcing value (Kantak et al, 2009). These findings suggest that decreased DAT 
function in OFC may lead to diminished reinforcing effects of cocaine in adult SHR that 
were treated with atomoxetine during adolescence. It is therefore possible that adolescent 
atomoxetine treatment may not increase cocaine abuse risk in adulthood, in contrast to 
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previous observations with methylphenidate. In adult outbred rats, acute atomoxetine 
administration reduced cocaine seeking (Economidou et al, 2011; Janak et al, 2012). 
However, the effects of chronic adolescent atomoxetine treatment on cocaine abuse risk 
in an animal model of ADHD have not yet been examined. Experiments 1 through 3 
address this clinically important question by evaluating the speed of acquisition of 
cocaine self-administration, and the efficacy and motivating influence of cocaine 
reinforcement, in adult rats following discontinuation of adolescent atomoxetine 
treatment. Importantly, treatment cessation is common in young adults with ADHD 
(McCarthy et al, 2009; Zetterqvist et al, 2012). 
 In addition to cocaine abuse risk resulting directly from the reinforcing value of 
cocaine, the environmental cues associated with cocaine use play a major role in the 
development of compulsive drug seeking and relapse behaviors. Although it is unknown 
whether ADHD influences reactivity to drug-related cues, cigarette smokers with ADHD 
report more frequent encounters with smoking-associated cues and perceive a stronger 
relationship between cues and smoking motivation than smokers without ADHD 
(Mitchell et al, 2013).  These findings suggest that drug-related cues may be more salient 
to individuals with ADHD. In cocaine-dependent subjects, videos involving the 
preparation or consumption of cocaine elicit greater activation in regions also known to 
be dysfunctional in ADHD, including the OFC and DLPFC, in comparison to healthy 
controls or videos involving the preparation or consumption of food (Wilcox et al, 2011). 
Similarly, in non-human primates, a visual stimulus associated with the reinforcing value 
of cocaine was found to increase activation in ventral OFC and VLPFC compared to a 
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control stimulus, and this activation was positively correlated with increasing preference 
for the cocaine-paired stimulus over the control stimulus (Nelissen et al, 2012). Because 
individuals with ADHD exhibit elevated OFC activation during reward-based tasks (von 
Rhein et al, 2015), exposure to cocaine and cocaine-related cues may exacerbate OFC 
dysfunction. This may lead to elevated cue reactivity and an increased risk of relapse in 
individuals with ADHD, given that cortical activation to cocaine cues is associated with 
treatment dropout and higher relapse rates in cocaine dependent patients (Kosten et al, 
2005).  
 The environmental cues associated with cocaine use are also linked to changes in 
dopamine-mediated transmission in cortical sites involved in ADHD. For example, 
systemic administration of a dopamine D1 receptor antagonist not only attenuated 
cocaine seeking behavior, but also reversed cocaine cue-induced increases in Fos 
expression in the basolateral amygdala and mPFC (Ciccocioppo et al, 2001), and infusion 
of D1 antagonists directly into the OFC reduced cocaine intake and cocaine seeking (Di 
Pietro et al, 2008). Notably, as reviewed above, DAT function in the mPFC and OFC is 
affected by adolescent ADHD medications (Somkuwar et al, 2013a, b). Previous work 
examining cue reactivity following adolescent methylphenidate treatment showed that 
prior methylphenidate exposure increased cocaine intake in adult SHR, and neither 
promoted nor protected against increased cocaine cue reactivity or relapse behaviors 
(Jordan et al, 2014). However, in outbred rats, acute atomoxetine infusions reduced cue-
induced cocaine seeking, both when cocaine was and was not available for self-
administration (Economidou et al, 2011; Janak et al, 2012). These findings suggest that 
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NET, the primary target of atomoxetine, plays an important role in regulating saliency of 
drug-associated cues. Thus, the effects of chronic adolescent atomoxetine treatment on 
cocaine cue reactivity in the SHR model of ADHD must be examined. Experiment 4 
addresses this clinically important question by measuring cocaine-seeking behavior under 
a second-order schedule of cocaine delivery and cue presentation. Cocaine seeking 
reflects cue reactivity (i.e., lever responding maintained by drug-paired cue presentation) 
and typically is measured under two experimental conditions: one condition during which 
cocaine is available for self-administration (maintenance testing) and another condition 
during which cocaine is not available for self-administration (reinstatement testing) 
(Kantak et al, 2002). 
 
 
Experiment 1: Acquisition of Cocaine Self-Administration Following Adolescent 
Atomoxetine Treatment 
 
 Experiment 1 tested the hypothesis that adult SHR acquire cocaine self-
administration faster, at which time more cocaine infusions would be earned and more 
lever responses would be made compared to adult WKY and WIS control strains. 
Elevation in these measures is suggestive of increased risk to rapidly develop compulsive 
patterns of cocaine abuse (Somkuwar et al, 2013a). Experiment 1 also tested the 
hypothesis that, in contrast to methylphenidate, treatment with a pharmacologically 
relevant dose of atomoxetine during adolescence does not further increase the speed to 
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acquire cocaine self-administration in adult SHR after adolescent treatment is 
discontinued. 
 
Materials and Methods 
 Animals and Treatments. All procedures were approved by the Institutional 
Animal Care and Use Committee at Boston University, and were performed in 
accordance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals (Eighth Edition). Male WKY/Cr, WIS/Cr, and SHR/Cr rats (Charles 
River Laboratories, Wilmington, MA, Kingston, NY or Raleigh, NC) arrived on postnatal 
day 25 (P25). SHR served as an animal model of ADHD, and WKY and WIS as inbred 
and outbred comparator strains, respectively. Using data from past studies in the Kantak 
laboratory, power analysis (beta = 90; p ≤ 0.05) indicated that group sizes of at least 6-7 
were needed to detect statistical differences across the various measures. Final group 
sizes for Experiment 1 included n = 8 for vehicle- and atomoxetine-treated WKY as well 
as vehicle-treated WIS and SHR, n = 10 for atomoxetine-treated SHR, and n = 11 for 
atomoxetine-treated WIS. Thus, these group sizes permitted meaningful analysis and 
interpretation of the data. 
 Rats were housed individually in plastic cages in a temperature-21–23°C and 
light- (07:30 hours on; 19:30 hours off) controlled vivarium. Rats were not given 
environmental enrichment because past research has demonstrated that environmental 
enrichment reduces ADHD-like symptoms in the SHR strain (Pamplona et al, 2009). Rats 
were allowed 3 days to acclimatize to new housing conditions in the Laboratory Animal 
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Care Facility prior to experimental initiation (see Figure 1 for an experimental timeline). 
The 3-day acclimation period is standard protocol in animal studies assessing cocaine  
self-administration (Roberts et al, 2002), neurochemistry (Mateo et al, 2005) as well as in 
studies using adolescent rats (Levin et al, 2007).  
 
   
 
 From P28 through P55, constituting the rat adolescent period (Spear, 2000), 
animals received once daily intraperitoneal (i.p.) injections of either a pharmacologically 
relevant dose of atomoxetine (0.3 mg/kg) dissolved in 0.9% sterile saline, or saline alone 
(2 ml/kg). The double injection volume was used to enable complete dissolution of 
atomoxetine. Treatments were administered once daily, Monday-Friday. This regimen 
mimics the weekend medication “holiday” that is sometimes elected by individuals with 
ADHD, in part to reduce the occurrence of side effects (American Academy of Pediatrics 
Committee on Children With Disabilities and Committee on Drugs, 1996; Faraone et al, 
2004; Martins et al, 2004). The relatively low dose of atomoxetine was chosen to increase 
 
Figure 1. Timeline of experimental events in Aim 1. 
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extracellular norepinephrine and dopamine concentrations primarily in PFC, through 
inhibition of NET (Bymaster et al, 2002). An i.p. route of administration was utilized due 
to poor bioavailability of atomoxetine in rats (Mattiuz et al, 2003). Food was restricted 
from P28-P55 to ~90% of a growth-adjusted free-feeding body weight to mimic 
conditions of past comparator studies (Harvey et al, 2011; 2013; Somkuwar et al 2013b). 
Animals had free access to water throughout experiments, and food was freely available 
after P55.  
 
 Surgery. Adolescent atomoxetine or vehicle treatment was discontinued on P56. 
On P67, rats were implanted with intravenous (i.v.) catheters connected to headmounts to 
enable cocaine self-administration. Animals were anesthetized with i.p. injections of 90 
mg/kg ketamine (Fort Dodge Animal Health, Fort Dodge, IA) and 8-10 mg/kg xylazine 
(Akorn, Decatur, IL). Subcutaneous (s.c.) Buprenex (0.05 mg/kg, Butler Schein, 
Columbus, OH) was given as a preemptive analgesic 5 minutes prior to anesthetization. 
Incisions were made to expose the right femoral vein and skull. A catheter constructed of 
silicon tubing (i.d. = 0.51, o.d. = 0.94 mm) was inserted s.c. between these incisions. The 
proximal end of the catheter was inserted into the right femoral vein and anchored to 
tissue underlying the vein using surgical silk and 0.5 mm square Teflon mesh (CR Bard 
Incorporated, Charlotte, NC). The distal end of the catheter was attached to a 22-gauge L-
shaped pedestal mount (Plastics One, Roanoke, VA). The pedestal was secured to the 
skull using four stainless-steel screws and acrylic cement. The stainless steel tubing 
exiting the pedestal was plugged with a sealed piece of Teflon tubing and covered with a 
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protective plastic outer screw cap. The antibiotic Baytril (5 mg/kg, i.v.; Bayer 
HealthCare, Shawnee, Mission, KS) was given for up to 5 days post-surgery to reduce the 
risk of systemic infection, and the anti-inflammatory Meloxicam (0.3 mg/kg, s.c., 
Boehringer Ingelheim Vetmedica, St. Joseph, MO) for 3 days post-surgery. Buprenex 
(0.025 mg/kg s.c.; Bulter Schein, Columbus, OH) was given for 48 hr following surgery 
or as needed, and 0.9% sterile saline was administered s.c. at least once and as needed 
subsequently (based on body weight loss) to maintain hydration.  
 Catheters were maintained by once daily flushing, Monday-Friday, with 0.2 ml of 
0.9% sterile saline containing heparin (30 IU /ml; Baxter Healthcare, Deerfield, IL) and 
Timentin (67 mg /ml; Glaxo-SmithKline, Research Triangle Park, NC). Before weekends 
and holidays, 0.08 ml of a locking solution consisting of glycerol (Sigma-Aldrich, St. 
Louis, MO) and 1000 IU/ml heparin was infused in a 3:1 ratio to fill catheter dead space 
and minimize the occurrence of blockages, thus prolonging the longevity of the catheter. 
The locking solution was removed and replaced with 0.1 ml of 0.9% sterile saline 
containing heparin (3 IU/ml) prior to resumption of behavioral procedures. Catheter 
patency was assessed weekly either by verifying the ability to withdraw blood or by 
observing rapid loss of muscle tone following a 0.1 ml infusion (10 mg/ml) of 
methohexital sodium (JHP Pharmaceuticals, Rochester, MI). In the event that patency 
was lost, catheters were repaired or replaced with a new catheter, implanted into the left 
femoral vein or the right or left jugular vein, under surgical anesthesia and post-operative 
care, as above. Animals were allowed to recover before resuming cocaine self-
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administration experiments. As a result, no animals were excluded from statistical 
analyses due to loss of catheter patency. 
 
 Testing Environment. Experimental chambers were equipped with two response 
levers, a white stimulus light mounted above the designated active lever, and a house 
light on the opposite wall (model ENV-008CT, Med Associates, St Albans, VT). 
Chambers were also fitted with a single channel fluid swivel (Instech Solomon, Plymouth 
Meeting, PA) and spring leash assembly, connected to a counterbalanced arm (Med 
Associates). During self-administration sessions, animals were leashed within the 
chamber via a hexnut connection to the pedestal mount, allowing free and comfortable 
movement throughout the chamber. Experimental chambers were enclosed in a sound-
attenuating cubicle, equipped with a fan for ventilation and an 8-ohm speaker to provide 
a background contextual cue consisting of white noise. The motor-driven syringe pumps 
(model ENV-018 M; Med Associates) used for cocaine delivery were located inside the 
cubicle. A PC-compatible computer programmed in Medstate Notation and connected to 
a Med Associates interface controlled experimental events from an adjacent room.  
 
 Cocaine Self-Administration. For intravenous self-administration, cocaine 
hydrochloride was dissolved in 0.9% sterile saline containing heparin (3 IU/ml). A 0.8 
mg/ml solution of cocaine was infused at a rate of 1.8 ml/min. The infusion duration was 
adjusted for body weight (1.2 s/100 g) to attain a training dose of 0.3 mg/kg cocaine, 
consistent with prior studies in SHR (Harvey et al, 2011).  
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 On P77, after 10 days of surgical recovery, animals were allowed to press the 
active lever (either left or right, counterbalanced across strains and treatments) for 
infusions of 0.3 mg/kg cocaine delivered under a fixed-ratio-1 (FR1) schedule of 
reinforcement. Under the FR1 schedule, each cocaine infusion required one response on 
the active lever and was paired with a 20-sec illumination of the stimulus light above the 
active lever. During this 20-sec period, the house light was extinguished and additional 
cocaine infusions could not be earned, though lever responses were still counted. The 20-
sec timeout period also served to prevent accidental overdose. After the 20 sec elapsed, 
the house light was re-illuminated. Responses on the inactive lever were recorded, but 
had no consequences. Importantly, animals received no external inducements to respond 
on either lever, such that acquisition of cocaine self-administration was entirely 
spontaneous. Sessions (2 hr) were conducted during the light phase, once daily, Monday-
Friday, at approximately the same time each day. Acquisition criterion was defined as 
earning ≥ 20 infusions for two consecutive sessions, and discriminating the active from 
inactive lever by a factor of 2 or greater (following Harvey et al, 2011). Animals were 
allowed a maximum of 25 sessions to spontaneously acquire cocaine self-administration, 
after which time lever pressing was facilitated via baiting of the active lever with a 45-mg 
chocolate-flavored food pellet (BioServ, Frenchtown, NJ). Baiting was necessary for one 
vehicle-treated WIS (32 sessions to acquire) and one atomoxetine-treated WIS (34 
sessions to acquire). All other animals reached acquisition criterion in 23 sessions or less. 
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 Data Analysis. Dependent measures in Experiment 1 included the number of 
sessions required to reach acquisition criterion (square root transformed prior to analysis 
due to non-normality), as well as cocaine infusions earned and active and inactive lever 
responses at acquisition criterion.  Measures were analyzed by two-factor (strain X 
treatment) ANOVAs, followed by post-hoc Tukey tests. 
   
Results 
 Sessions to reach the acquisition criterion for the 0.3 mg/kg training dose of 
cocaine are shown in Figure 2. Strains differed significantly (F (2, 47) = 7.0, p ≤ 0.002), 
and there was a trend for a strain X treatment interaction (F (2, 47) = 2.7, p ≤ 0.07). 
Overall, SHR acquired cocaine self-administration faster than WKY and WIS (p ≤ 0.04 
and 0.002, respectively). Strain comparisons within each treatment revealed that in 
vehicle-treated rats, SHR acquired cocaine self-administration faster than WKY (p ≤ 
0.02). In atomoxetine-treated rats, both SHR and WKY acquired cocaine self-
administration faster than WIS (p ≤ 0.01 and 0.05, respectively). Treatment comparisons 
within each strain revealed that in WKY, acquisition of cocaine self-administration was 
faster after atomoxetine than vehicle (p ≤ 0.03). Notably, atomoxetine did not alter 
acquisition speed in SHR or in the WIS control.  
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 The number of cocaine infusions earned at the acquisition criterion for the 0.3 
mg/kg training dose of cocaine is shown in Figure 3. Strains differed significantly (F (2, 
47) = 6.2, p ≤ 0.004), but the treatment factor and its interaction with strain were not 
significant. Post-hoc comparisons showed that, overall, SHR earned more cocaine 
infusions than WKY (p ≤ 0.003), and there was a trend towards more infusions compared 
to WIS (p ≤ 0.09).  
 
Figure 2. Number of sessions required to reach acquisition criterion in adult WKY, 
WIS, and SHR, following vehicle or atomoxetine treatment during adolescence 
(Mean ± SEM). * p ≤ 0.05 compared to both other strains. ^ p ≤ 0.05 compared to 
vehicle treatment in the same strain.  
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 Active lever responses at criterion are shown in Figure 4. Strains again differed 
significantly (F (2, 47) = 4.5, p ≤ 0.02), and there was a trend towards a strain X 
treatment interaction (F (2, 47) = 2.7, p ≤ 0.08). Post-hoc comparisons showed that, 
overall, SHR made more active lever responses than WKY (p ≤ 0.02), and there was a 
trend towards more active lever responses than WIS (p ≤ 0.07). Treatment comparisons 
within each strain revealed that in adult SHR, active lever responses were greater after 
adolescent atomoxetine than vehicle (p ≤ 0.006). Strain comparisons within each 
treatment condition revealed that in atomoxetine-treated rats, SHR made more active 
lever responses than WKY and WIS (p ≤ 0.003 and 0.006, respectively). There were no 
strain differences in active lever responses among vehicle-treated rats at criterion. With 
respect to inactive lever responses, there were no strain or treatment differences at 
 
Figure 3. Number of cocaine infusions earned at acquisition criterion in adult WKY, 
WIS, and SHR, following vehicle or atomoxetine treatment during adolescence 
(Mean ± SEM). & p ≤ 0.05 compared to WKY overall.  
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criterion, and each strain discriminated the active from inactive lever by a factor of 2 or 
greater (9:1 for WKY, 20:1 for WIS, and 4:1 for SHR, on average). 
 
 
 
 
Experiment 2: Fixed-Ratio Cocaine Dose-Response Functions in Adulthood 
Following Adolescent Atomoxetine Treatment 
 
 Experiment 2 tested the hypothesis that the efficacy of cocaine reinforcement is 
elevated in adult SHR compared to WKY or WIS, such that SHR earn more cocaine 
infusions and make more responses on the active lever across a range of doses under a 
FR1 schedule of reinforcement. Experiment 2 also tested the hypothesis that, in contrast 
 
Figure 4. Number of active lever responses made at acquisition criterion in adult 
WKY, WIS, and SHR, following vehicle or atomoxetine treatment during 
adolescence (Mean ± SEM). & p ≤ 0.05 compared to WKY overall. ^ p ≤ 0.05 
compared to vehicle treatment in the same strain.   
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to the effects of methylphenidate, treatment with a pharmacologically relevant dose of 
atomoxetine during adolescence does not increase the efficacy of cocaine reinforcement 
in adult SHR after adolescent treatment is discontinued. 
 
Materials and Methods 
 Animals and Treatments. Following achievement of the acquisition criterion in 
Experiment 1, the same groups of animals were allowed to continue responding under an 
FR1 schedule for the 0.3 mg/kg training dose, until active lever responses and the number 
of cocaine infusions varied ≤ 15% for 5 consecutive sessions. A range of cocaine unit 
doses (0.003, 0.01, 0.03, 0.1, and 1.0 mg/kg/infusion) was then substituted in place of the 
training dose in a pseudo-random order, every Tuesday and Friday. The 0.3 mg/kg 
training dose was available on the intervening days (Monday, Wednesday, and 
Thursday). As above, sessions were 2 hours in length and were conducted during the light 
phase once daily, Monday-Friday, at approximately the same time each day. After the full 
FR cocaine dose-response functions were completed, rats were allowed to return to 
baseline responding for the 0.3 mg/kg training dose. Two atomoxetine-treated WIS and 
two atomoxetine-treated SHR expired prior to completion of Experiment 2, and were thus 
excluded from Experiment 2 data analyses.   
 
 Data Analysis. Dependent measures in Experiment 2 included the number of 
cocaine infusions earned, and active and inactive lever responses for each cocaine dose. 
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Measures were analyzed by three-factor (strain X treatment X dose) ANOVAs, with 
repeated measures for dose, followed by post-hoc Tukey tests.  
 
Results 
 Cocaine dose-response functions based on the number of infusions earned under 
the FR1 schedule of reinforcement are shown in Figure 5. For the three-way ANOVA, 
strain (F (2, 43) = 18.4, p ≤ 0.001) and dose (F (5, 215) = 185.5, p ≤ 0.001) differed, and 
there was also a strain X dose interaction (F (10, 215) = 9.3, p ≤ 0.001). The treatment 
factor and its interactions with strain and/or dose were not significant, indicating that 
adolescent atomoxetine treatment did not further increase cocaine intake in SHR or in 
control strains. Overall, SHR earned more cocaine infusions than WKY and WIS (p ≤ 
0.001). Further testing of the strain X dose interaction indicated that SHR earned more 
infusions than WKY for cocaine doses ranging from 0.003 to 0.3 mg/kg (ps ≤ 0.04), and 
more infusions than WIS for cocaine doses ranging from 0.003 to 0.1 mg/kg (ps ≤ 0.01, 
except at 0.01mg/kg, where p ≤ 0.08). In addition, WIS earned more infusions than WKY 
at 0.1 mg/kg (p ≤ 0.001). No strain differences were observed at 1.0 mg/kg.  
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 Analyses of the cocaine dose–response functions based on the number of active 
lever responses (Figure 6) were similar to the number of infusions earned. For the three-
way ANOVA, strain (F (2, 43) = 4.9, p ≤ 0.01) and dose (F (5, 215) = 36.9, p ≤ 0.001) 
differed significantly, and there was a strain X dose interaction (F (10, 215) = 3.2, p ≤ 
0.001). The treatment factor and its interactions with strain and/or dose were not 
significant, indicating that adolescent atomoxetine treatment did not further increase 
cocaine-maintained responding in SHR or in control strains. Post-hoc comparisons 
showed that SHR overall made more active lever responses than WKY (p ≤ 0.01), but 
SHR were not different from WIS. Further testing of the strain X dose interaction 
revealed that SHR made more active lever responses at the 0.03 and 0.1 mg/kg doses than 
 
Figure 5. Cocaine dose-response functions based on infusions earned under a FR1 
schedule of reinforcement by adult WKY, WIS, and SHR, following vehicle or 
atomoxetine treatment during adolescence (Mean ± SEM). * p ≤ 0.05 compared to 
both other strains. § p ≤ 0.05 compared, overall, to the same dose in WKY.  
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WKY and WIS (ps ≤ 0.05). Furthermore, WIS made more active lever responses at 0.1 
mg/kg than WKY (p ≤ 0.003). No strain differences at the other doses were found. There 
were no strain or treatment differences in inactive lever responding. 
 
 
 
 
 Experiment 3: Progressive-Ratio Cocaine Dose-Response Functions in Adulthood 
Following Adolescent Atomoxetine Treatment 
 
 Experiment 3 tested the hypothesis that the motivating influence of cocaine 
reinforcement is elevated in adult SHR compared to WKY or WIS, such that SHR work 
 
Figure 6. Cocaine dose-response functions based on active lever responses made 
under a FR1 schedule of reinforcement by adult WKY, WIS, and SHR, following 
vehicle or atomoxetine treatment during adolescence (Mean ± SEM).  & p ≤ 0.05 
compared to WKY overall. § p ≤ 0.05 compared, overall, to the same dose in WKY.  
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harder to earn cocaine reinforcement, earn more cocaine infusions and make more active 
lever responses across a range of doses under a progressive ratio (PR) schedule. 
Experiment 3 also tested the hypothesis that, in contrast to methylphenidate, treatment 
with a pharmacologically relevant dose of atomoxetine during adolescence does not 
increase the motivating influence of cocaine reinforcement in adult SHR after adolescent 
treatment is discontinued. 
 
Materials and Methods 
 Animals and Treatments. Once rats returned to baseline levels of responding for 
0.3 mg/kg cocaine under the FR1 schedule in Experiment 2, a PR schedule of 
reinforcement was instituted in the same groups of animals. The PR schedule involved a 
geometric increment in the number of responses required to earn each cocaine infusion 
(e.g., 1, 2, 4, 6, 9, 12, 15, 20, 25, 32, 40, 50, 62, 77, 95, 118, 145, 178, 219, 268, 328, 
402, 492, 603, etc., following Loh & Roberts, 1990). Sessions were terminated when a rat 
failed to reach the next response requirement within 1 hour of the previous infusion. The 
PR breakpoint was defined as the last FR response requirement completed to earn a 
cocaine infusion. Animals were allowed to respond for 0.3 mg/kg cocaine under the PR 
schedule until breakpoints, cocaine infusions, and active lever responses varied ≤ 15% for 
5 consecutive sessions. Cocaine test doses were then substituted (0.01, 0.1, 0.3, and 1.0 
mg/kg) in descending order (following Harvey et al, 2011), with 2-3 consecutive sessions 
allocated to each test dose. Baseline responding was reestablished for the 0.3 mg/kg dose 
after the full PR dose-response function was completed to ensure that PR baseline 
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performance was stable after dose-substitution testing. As above, self-administration 
sessions were conducted during the light phase once daily, Monday-Friday, at 
approximately the same time each day. One atomoxetine-treated WIS expired prior to 
completion of Experiment 3, and was thus excluded from Experiment 3 data analyses. At 
the end of Experiment 3, all animals were humanely euthanized with an overdose of 
sodium pentobarbital (Euthasol). 
 
 Data Analysis. Dependent measures in Experiment 3 included PR breakpoints, the 
number of cocaine infusions earned, and active and inactive lever responses for each 
cocaine dose. Measures were analyzed by three-factor (strain X treatment X dose) 
ANOVAs, with repeated measures for dose, followed by post-hoc Tukey tests.  
 
Results 
 Cocaine dose-response functions based on the PR breakpoint are shown in Figure 
7. For the three-way ANOVA, strain (F (2, 42) = 10.1, p ≤ 0.001) and dose (F (3, 126) = 
53.3, p ≤ 0.001) differed. The treatment factor and its interactions with strain and/or dose 
were not significant, indicating that adolescent atomoxetine treatment did not further 
increase the motivating influence of cocaine in SHR or in control strains. Overall, SHR 
reached higher breakpoints than WKY and WIS (p ≤ 0.001 and 0.01, respectively). 
Further analysis of the dose factor revealed that animals maintained the highest 
breakpoints at 1.0 mg/kg, which differed from all other doses, and maintained the lowest 
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breakpoints at 0.01 mg/kg, which also differed from all other doses (ps ≤ 0.001 - 0.03). 
Breakpoints maintained by 0.3 and 0.1mg/kg did not differ from each other.  
 
 
 The PR cocaine dose-response functions based on the number of infusions earned 
are shown in Figure 8. For the three-way ANOVA, strain (F (2, 42) = 17.1, p ≤ 0.001) 
and dose differed significantly (F (3, 126) = 158.4, p ≤ 0.001). The treatment factor and 
its interactions with strain and/or dose were not significant, indicating that adolescent 
atomoxetine treatment did not further increase cocaine intake in SHR or in control 
strains. Post-hoc tests showed that, overall, SHR earned more cocaine infusions than 
WKY and WIS (p ≤ 0.001). Further analysis of the dose factor showed that animals 
earned the greatest number of cocaine infusions at the 1.0 mg/kg dose compared to the 
 
Figure 7. Cocaine dose-response functions, based on breakpoints reached under a PR 
schedule of reinforcement, by adult WKY, WIS, and SHR following vehicle or 
atomoxetine treatment during adolescence (Mean ± SEM). * p ≤ 0.05 compared to 
both other strains.  
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three other doses (ps ≤ 0.001), and earned the fewest cocaine infusions at the 0.01 mg/kg 
dose compared to the three other doses (ps ≤ 0.001). In addition, more cocaine infusions 
were earned at the 0.3 mg/kg dose than at the 0.1 mg/kg dose (p ≤ 0.001). 
 
 
 
 The PR cocaine dose-response functions based on active lever responses are 
shown in Figure 9. For the three-way ANOVA, strain (F (2, 42) = 10.5, p ≤ 0.001) and 
dose (F (3, 126) = 51.5, p ≤ 0.001) differed significantly. The treatment factor and its 
interactions with strain and/or dose were not significant, indicating that adolescent 
atomoxetine treatment did not further increase cocaine-maintained responding in SHR or 
 
Figure 8. Cocaine dose-response functions, based on infusions earned under a PR 
schedule of reinforcement, by adult WKY, WIS, and SHR following vehicle or 
atomoxetine treatment during adolescence (Mean ± SEM). * p ≤ 0.05 compared to 
both other strains.  
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in control strains. Post-hoc testing showed that, overall, SHR made more active lever 
responses than WKY and WIS (p ≤ 0.001 and p ≤ 0.008, respectively). Further analysis 
of the dose factor revealed that animals made the most active lever responses for the 1.0 
mg/kg cocaine dose, compared to the three other doses (ps ≤ 0.001), and the fewest active 
lever responses for 0.01 mg/kg cocaine dose, compared to the three other doses (ps ≤ 
0.001, except at the 0.1 mg/kg dose where p ≤ 0.05). Active lever responding for the two 
intermediate cocaine doses, 0.3 mg/kg and 0.1 mg/kg, did not differ from each other. 
There were no strain or treatment differences in inactive lever responding. 
 
 
 
Figure 9. Cocaine dose-response functions, based on active lever responding under a 
PR schedule of reinforcement, by adult WKY, WIS, and SHR following vehicle or 
atomoxetine treatment during adolescence (Mean ± SEM). * p ≤ 0.05 compared to 
both other strains.  
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Experiment 4: Cocaine Cue Reactivity and Relapse Behavior in Adulthood 
Following Adolescent Atomoxetine Treatment 
 
 Experiment 4 tested the hypothesis that adult SHR are most reactive to cocaine-
related cues, such that SHR would emit more cocaine-seeking responses than WKY and 
WIS under a second-order schedule. Experiment 4 also tested the hypothesis that 
treatment with a pharmacologically relevant dose of atomoxetine during adolescence 
does not increase reactivity to cocaine cues in adult SHR after adolescent treatment is 
discontinued.  
 
 Materials and Methods 
 New groups of SHR, WKY and WIS were used in Experiment 4. The housing, 
treatments, surgical procedures, and testing environments were identical to those detailed 
in Experiment 1.  
 
 Experiment 4a: Maintenance Testing under a Second-Order Schedule. On post-
natal day 76, following recovery from surgical implantation of the i.v. catheter, rats were 
allowed to lever press for 45-mg chocolate-flavored food pellets (BioServ, Frenchtown, 
NJ) under a FR1 schedule to facilitate acquisition of lever responding. The next day, rats 
began self-administration training for 0.3 mg/kg cocaine under an FR1 schedule. This 
dose was selected because it produces the highest rate of responding under a second-
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order schedule of cocaine delivery in rats (Kantak et al, 2009). This dose also was used 
previously to examine the effects of adolescent methylphenidate treatment on cocaine 
self-administration behavior studied under a second-order schedule (Jordan et al, 2014). 
Sessions were initiated with illumination of the house light and onset of white noise. 
Cocaine infusions under the FR1 schedule coincided with 20-sec presentation of the 
stimulus light, while the house light was extinguished. During this period, additional 
cocaine infusions could not be earned, to reduce risk of accidental overdose. The house 
light was re-illuminated and the stimulus light extinguished after the 20-sec timeout 
period. Rats were trained incrementally to a terminal fixed-interval (FI) based second-
order schedule, designated FI 5-min [FR5 : S]. Under this schedule, every fifth lever 
press (FR5) produced a 2-sec cue light, and the first FR5 response unit completed after 
the 5-min FI elapsed resulted in a cocaine infusion coinciding with 20-sec presentation of 
the stimulus light, after which the FI 5-min component was again in effect. Responses on 
the inactive lever were also recorded throughout the session, but had no consequences. 
Self-administration sessions were 2 hours in length and were conducted during the light 
phase once daily, Monday-Friday, at approximately the same time each day. Training 
under the second-order schedule continued until rats reached stable levels of responding 
(≤ 15% variation in active lever responding and ≤ 33% of total responses on the inactive 
lever) for a minimum of 5 sessions. This stable baseline period served as the maintenance 
testing phase. Final group sizes for all phases of Experiment 2 included n = 8 for vehicle- 
and atomoxetine-treated WKY and SHR as well as atomoxetine-treated WIS, and n = 9 
for vehicle-treated SHR.  
  
43	  
 Experiment 4b: Extinction Training. Following completion of the maintenance 
testing phase, rats underwent response extinction training, to reduce the learned 
association between lever responding and cocaine reinforcement, while leaving the 
association between cocaine-related cues and cocaine reinforcement intact. During this 
phase, the house light was illuminated throughout the session, but the cue light and white 
noise were not presented, and cocaine infusions could not be earned. Active and inactive 
lever responses therefore had no consequences. Extinction training continued for a 
minimum of 10 sessions or until criterion was reached, defined as active lever responding 
that was ≤ 10% of the maintenance baseline for 3 consecutive sessions (constituting the 
extinction baseline). If rats did not reach criterion, a maximum of 21 extinction sessions 
was imposed. As above, sessions were 2 hours in length and were conducted during the 
light phase once daily, Monday-Friday.  
 
 Experiment 4c: Cue-Induced Reinstatement Testing. Following achievement of 
extinction criterion, rats underwent cue-induced reinstatement testing to assess the ability 
of cocaine-paired cues to induce relapse to previously extinguished cocaine-seeking 
behavior. Relapse to cocaine seeking is shown by a significantly greater number of active 
lever responses during the reinstatement test relative to the extinction baseline. During 
this phase, the discrete stimulus light and contextual white noise cues were presented 
under contingencies identical to self-administration training under the second-order 
schedule, but cocaine infusions could not be earned. Reinstatement testing sessions were 
1 hour in duration and were conducted during the light phase once daily, Monday-Friday. 
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All rats underwent 7 reinstatement sessions. At the end of Experiment 4c, all animals 
were humanely euthanized with an overdose of sodium pentobarbital (Euthasol). 
 
 Data Analysis. Dependent measures in Experiment 4 included the number of 
cocaine infusions earned, active and inactive lever responses, and the number of sessions 
required to reach extinction criterion. Measures were analyzed by three-factor (strain X 
treatment X reinstatement session, or strain X treatment X phase) ANOVAs, with 
repeated measures for session or phase (extinction vs. reinstatement), followed by post-
hoc Tukey tests.  
 
Results 
 Experiment 4a: Maintenance Testing under a Second-Order Schedule. Cocaine 
intake during maintenance testing under the second-order schedule is shown in Figure 10. 
Strains differed in number of cocaine infusions (F (2, 42) = 16, p ≤ 0.001), with adult 
SHR earning more infusions than WKY and WIS (p ≤ 0.001). Main and interaction 
effects of treatment were not significant, and further analysis confirmed that adolescent 
atomoxetine did not significantly alter cocaine intake compared to vehicle treatment in 
any strain during maintenance testing. 
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 Active lever responses during maintenance testing and during the first drug-free 
interval of the final maintenance testing session (i.e., the first 5-min FI of the session 
occurring prior to delivery of the initial cocaine infusion) are shown in Figures 11 and 12, 
respectively. During maintenance testing, strains differed (F (2, 42) = 29.6, p ≤ 0.001), 
with adult SHR making more active lever responses than WKY and WIS (p ≤ 0.001). 
During the first drug-free interval, there was a main effect of strain (F (2, 42) = 31.4, p ≤ 
0.001) and a strain X treatment interaction (F (2, 42) = 4.1, p ≤ 0.02). Overall, adult SHR 
made more active lever responses than WKY and WIS during the first drug-free interval 
(p ≤ 0.001). Post-hoc testing of the interaction revealed that adolescent atomoxetine 
reduced active lever responses compared to vehicle treatment in adult SHR during the 
first drug-free interval (p ≤ 0.005). In contrast, adolescent atomoxetine did not 
 
Figure 10. Cocaine intake during maintenance testing under a second-order schedule 
of reinforcement in adult WKY, WIS, and SHR, following vehicle or atomoxetine 
treatment during adolescence (Mean ± SEM). * p ≤ 0.05 compared to both other 
strains.  
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significantly alter active lever responses compared to vehicle treatment during the first 
drug-free interval in WKY or WIS. There were no significant strain or treatment 
differences in inactive lever responding during maintenance testing. 
 
 
Figure 11. Active lever responding averaged across the maintenance testing baseline 
in adult WKY, WIS, and SHR, following vehicle or atomoxetine treatment during 
adolescence (Mean ± SEM). * p ≤ 0.05 compared to both other strains.  
 
Figure 12. Active lever responding during the first drug-free interval of the final 
maintenance testing session in adult WKY, WIS, and SHR, following vehicle or 
atomoxetine treatment during adolescence (Mean ± SEM). * p ≤ 0.05 compared to 
both other strains. ^ p ≤ 0.05 compared to vehicle treatment in the same strain. 
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 Experiment 4b: Extinction Training. The number of sessions to reach the 
extinction criterion is shown in Figure 13. There were strain differences in number of 
sessions (F (2, 42) = 6.1, p ≤ 0.005), with WKY and SHR requiring more sessions than 
WIS (p ≤ 0.04 and p ≤ 0.005 respectively). SHR and WKY did not differ. A strain X 
treatment interaction also was found (F (2, 42) = 3.9, p ≤ 0.02). Post-hoc testing revealed 
that adult SHR receiving adolescent atomoxetine required more sessions to reach 
extinction criterion than SHR receiving vehicle (p ≤ 0.006). Treatments did not differ in 
WKY and WIS. Analysis of the extinction baseline (Figure 14) revealed that the relative 
degree of extinguished responding (values expressed as percentage of the maintenance 
baseline) was not different between treatments and across strains. Inactive lever 
responses differed by strain (F (2, 42) = 3.7, p ≤ 0.03), with SHR making more inactive 
lever responses (24 ± 5) than WIS (11 ± 3, p ≤ 0.02), but not WKY (15 ± 4). 
 
 
Figure 13. Number of sessions required to reach extinction criterion in adult WKY, 
WIS, and SHR, following vehicle or atomoxetine treatment during adolescence 
(Mean ± SEM). # p ≤ 0.05 compared to WIS overall. ^ p ≤ 0.05 compared to vehicle 
treatment in the same strain. 
  
48	  
  
 
 Experiment 4c: Cue-Induced Reinstatement Testing. The number of active lever 
responses during reinstatement testing, averaged across the seven sessions of testing, and, 
for comparison, the first hour of the extinction baseline is shown in Figure 15. Three-
factor ANOVA revealed main effects of phase (F (1, 42) = 213.9, p ≤ 0.001) and strain (F 
(2, 42) = 77.1, p ≤ 0.001), and a strain X treatment X phase interaction (F (2, 42) = 3.1, p 
≤ 0.05). Post-hoc testing of the interaction indicated that cue re-exposure during the 
reinstatement phase reinstated cocaine-seeking responses above extinction levels in each 
group (p ≤ 0.002) and that adult SHR reinstated more cocaine-seeking responses than 
WKY or WIS (p ≤ 0.001). In addition, SHR emitted more responses during the first hour 
of the extinction baseline than WKY or WIS (p ≤ 0.001). During reinstatement testing, 
adolescent atomoxetine treatment attenuated cocaine-seeking responses compared to 
 
Figure 14. Active lever responding during the extinction baseline, expressed as a 
percentage of the maintenance testing baseline, in adult WKY, WIS, and SHR, 
following vehicle or atomoxetine treatment during adolescence (Mean ± SEM).  
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vehicle only in adult SHR (p ≤ 0.032). There were no strain or treatment differences in 
inactive lever responding. 
 
 
 Cocaine-seeking responses during reinstatement testing were additionally 
analyzed with reinstatement test session as a factor using a three-factor (strain X 
treatment X reinstatement session) ANOVA, with repeated measures for session. Active 
lever responses during the seven individual reinstatement testing sessions are shown in 
Figure 16. There was a main effect of strain (F (2, 42) = 77.5, p ≤ 0.001). Further 
comparisons revealed that adult SHR overall made more active lever responses than 
WKY and WIS (p ≤ 0.001). There were no significant effects of treatment, nor 
interactions between strain and treatment or reinstatement session in the three-way 
 
Figure 15. Active lever responding averaged across the seven reinstatement test 
sessions in adult WKY, WIS, and SHR, following vehicle or atomoxetine treatment 
during adolescence. For comparison, active lever responses during the first hour of 
extinction training were averaged across the extinction baseline and are depicted in 
the gray bars (Mean ± SEM). * p ≤ 0.05 compared to both other strains. ^ p ≤ 0.05 
compared to vehicle treatment in the same strain. 
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ANOVA. 
 
 
 
Discussion 
 
 Strain Differences in Cocaine Abuse Risk and Cocaine Cue Reactivity 
 The current work reproduces and extends previous research indicating that SHR 
are a valuable model of comorbid ADHD and cocaine abuse (Baskin et al, 2015; Harvey 
et al, 2011). As hypothesized, SHR exhibited elevated cocaine abuse risk compared to 
both WKY and WIS control strains, characterized by faster acquisition of cocaine self-
 
Figure 16. Active lever responses during each reinstatement test session in adult 
WKY, WIS, and SHR, following vehicle or atomoxetine treatment during 
adolescence. For comparison, active lever responses during the first hour of 
extinction (Ext) training, averaged across the extinction baseline, are also shown 
(Mean ± SEM). * p ≤ 0.05 compared to both other strains.  
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administration and increased efficacy and motivating influence of cocaine reinforcement. 
More specifically, during the acquisition phase adult SHR spontaneously acquired 
cocaine self-administration faster, earned more cocaine infusions, and made more 
cocaine-maintained responses than adult WKY and WIS. Importantly, acquisition of 
cocaine self-administration is dependent on dopamine D1 receptors in the nucleus 
accumbens shell, as silencing of D1a receptors in the shell region prevents acquisition of 
cocaine self-administration in outbred rats (Pisanu et al, 2015). While the effect of 
silencing D1 receptors in the accumbens shell in SHR have not been investigated, SHR 
exhibit elevated Fos expression in the nucleus accumbens core as well as the shell areas 
(Ohno et al, 2012). Fos-expressing neurons in nucleus accumbens are known to interact 
with D1 receptors, and thus have a critical role in cocaine reinforcement (Anderson et al, 
2003; Bari & Pierce, 2005; Ikemoto et al, 1997). Together, these observations suggest 
that elevated activity at D1 receptors in the nucleus accumbens may contribute to faster 
acquisition of cocaine self-administration in SHR, relative to WKY or WIS control 
strains. Consistent with this view, D1 receptor expression in the nucleus accumbens is 
elevated in SHR compared to the WKY control strain (Ohno et al, 2012), 
 Under both FR and PR schedules, SHR continued to exhibit increased cocaine 
abuse risk, earning more cocaine infusions and making more cocaine-maintained 
responses across a range of doses, consistent with prior studies (Baskin et al, 2015; 
Harvey et al, 2011). Vulnerability to cocaine abuse is reflected by vertical (upward) shifts 
in FR and PR dose-response functions (Piazza et al, 2000). As with acquisition, 
motivation to self-administer cocaine under the PR schedule, in particular, is mediated by 
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D1 receptors, as infusion of D1 receptor antagonists in the nucleus accumbens, VTA, and 
mPFC reduces PR breakpoints for cocaine (McGregor & Roberts, 1993; 1995; Ranaldi & 
Wise, 2001). Interestingly, high-novelty seeking rats exhibit upward shifts in cocaine 
dose-response functions (Piazza et al, 2000). This behavior has been attributed to 
increased dopamine release in the nucleus accumbens following cocaine administration, 
as well as to elevated DAT function and D1 receptor expression in the nucleus 
accumbens (Hooks et al, 1991; 1994). Like individuals with ADHD, SHR exhibit high 
novelty seeking (dela Peña et al, 2015; Donfrancesco et al, 2015), as well as elevated 
striatal DAT density (Roessner et al, 2010) and increased D1 receptor expression (Ohno 
et al, 2012) in the nucleus accumbens, compared to WKY.  These differences may 
contribute to the vertical shifts in cocaine dose-response functions observed in SHR. 
 Consistent with the hypotheses and with prior studies (Jordan et al, 2014), cocaine 
intake and cocaine seeking was also greater in SHR compared to WKY or WIS under the 
second-order schedule of reinforcement. High levels of cocaine seeking by SHR both 
when cocaine was (maintenance testing) and was not (the first drug-free interval of 
maintenance testing and reinstatement testing) available for self-administration suggest 
that SHR exhibit heightened cocaine cue reactivity compared to WKY or WIS. Notably, 
SHR extinguished active lever responding within the same timeframe as WKY, but more 
slowly than WIS. The observation that SHR exhibit similar rates of extinction compared 
to WKY suggests that extinction learning is not impaired in SHR, but rather may be 
faster in WIS. High levels of cocaine seeking by SHR during reinstatement testing are 
therefore not likely due to impaired extinction learning, but rather further reflect 
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heightened cocaine cue reactivity in this strain. SHR also often made more inactive lever 
responses than WKY and WIS, which may relate to hyperactivity in SHR when 
reinforcers are infrequent (Sagvolden et al, 2005). Nonetheless, SHR remained goal-
directed, as active lever responding was substantially greater than inactive lever 
responding throughout maintenance and reinstatement testing.  
 Control strains did not differ in the various measures of cocaine abuse risk, with 
the exception that WIS earned more cocaine infusions and made more active lever 
responses than WKY for 0.1 mg/kg cocaine under the FR1 schedule. Importantly, the 0.1 
mg/kg dose produced peak rates of responding in all strains under the FR1 schedule. 
Cocaine doses commonly abused in humans and those associated with peak rates of 
responding in non-human primates produce similar levels of striatal DAT occupancy 
(Wilcox et al, 2002), suggesting that strain differences in cocaine self-administration may 
reflect strain differences in DAT function or expression. Compared with WIS, WKY 
exhibit decreased DAT density in the nucleus accumbens (Jiao et al, 2003). The 0.1 
mg/kg cocaine dose may therefore be a less efficacious reinforcer for WKY relative to 
WIS and SHR, due to lower DAT expression in reward-associated regions.  
 
Effects of Adolescent Atomoxetine on Cocaine Abuse Risk and Cue Reactivity 
 Consistent with the hypotheses, adolescent treatment with a pharmacologically 
relevant dose of atomoxetine did not further enhance the speed to acquire cocaine self-
administration, or the efficacy and motivating influence of cocaine reinforcement in adult 
SHR, in contrast to previous observations with methylphenidate. An exception was that 
  
54	  
atomoxetine-treated SHR made more active lever responses at the acquisition criterion, 
without earning more cocaine infusions. These findings indicate that responding was 
greater during the 20-second timeout periods that followed each cocaine infusion and 
during which the cue light was illuminated. Acute atomoxetine treatment is known to 
have cognitive enhancing effects, via increased noradrenergic transmission (Arnsten & 
Pliszla, 2011; Gamo et al, 2010; Janak et al, 2012). Therefore, it is possible that prior 
adolescent atomoxetine treatment increased the salience of cocaine-related cues in SHR 
during acquisition when cocaine was first available for self-administration, but not later 
after chronic exposure to cocaine. Rather, adolescent atomoxetine modestly decreased 
cue reactivity in adult SHR when cocaine was not available, both during the first drug-
free interval of maintenance testing and during cue-induced reinstatement, when 
responding was averaged across all seven reinstatement test sessions. Adolescent 
atomoxetine treatment also increased the number of sessions required to extinguish lever 
responding in adult SHR. However, all strains and treatment groups extinguished active 
lever responding to the same relative degree prior to reinstatement testing (i.e., ≤ 10% of 
the self-administration baseline). The slower rate of extinction in SHR did not result in 
elevated cocaine abuse risk, as assessed during subsequent reinstatement testing.  
 Adolescent atomoxetine treatment did not alter any measure of cocaine abuse risk 
in adult WIS, the outbred control strain. Although a previous study reported attenuated 
cocaine seeking during second-order maintenance testing in an outbred rat strain 
following acute administration of atomoxetine (Economidou et al, 2011), these effects 
were only observed with doses that were 3- to 10-fold higher (1 or 3 mg/kg) than the 
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more 0.3 mg/kg dose used in the present work, which may more closely resemble doses 
used in the treatment of ADHD (Bymaster et al, 2002). Interestingly, in contrast to its 
effects in SHR and WIS, adolescent atomoxetine treatment speeded acquisition of 
cocaine self-administration in adult WKY. Atomoxetine also differentially influenced 
strain performance on a strategy set shifting task, such that learning speed during the 
initial discrimination phase was faster in adolescent SHR, but slower in adolescent WKY 
and WIS, after atomoxetine treatment (Harvey et al, 2013). Taken together, these results 
emphasize the importance of concurrent evaluation of both inbred and outbred control 
strains when assessing the effects of adolescent ADHD medication in the SHR model.  
 In conclusion, these experiments further demonstrate the value of the SHR as a 
model for comorbid ADHD and cocaine abuse risk, and suggest that cocaine cue 
reactivity may contribute to the elevated risk of cocaine use disorder in individuals with 
ADHD. However, further studies evaluating physiological measures such as skin 
conductance, heart rate, or hemodynamic neural responses to drug cues in individuals 
with ADHD are necessary to confirm this hypothesis. Contrary to previous findings with 
methylphenidate, adolescent atomoxetine treatment did not further enhance cocaine abuse 
risk in SHR. Atomoxetine may therefore be a suitable alternative to methylphenidate 
treatment in teenagers with ADHD, in whom the risk of later drug abuse may be a 
concern. Moreover, while these experiments do not raise critical concerns about the 
safety of atomoxetine, they do emphasize the importance of accurate diagnosis of ADHD. 
In the WKY control strain, atomoxetine speeded acquisition of cocaine self-
administration. Misdiagnosis of ADHD, and subsequent atomoxetine treatment in teens 
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could therefore result in a more rapid development of abuse of cocaine, if the drug is 
sampled. 
 
 
 
CHAPTER THREE.   
 
Aim 2: Effects of an Alternative Stimulant Medication on Prefrontal Cortex 
Function during Adolescence and Cocaine Abuse Risk and Cue Reactivity in 
Adulthood 
 
Introduction 
 The experiments in Aim 1 tested the hypothesis that, in contrast to the stimulant 
methylphenidate, the non-stimulant ADHD medication, atomoxetine, does not increase 
cocaine abuse risk when treatment is initiated during adolescence. The findings suggest 
that adolescent treatment with atomoxetine does not increase cocaine abuse risk and may 
modestly decrease reactivity to cocaine-related cues. Despite these observations, 
atomoxetine conveys some disadvantages compared to methylphenidate. For example, 
atomoxetine often requires a week or longer to begin alleviating ADHD symptoms 
(Sibley et al, 2014). Moreover, as a non-stimulant, atomoxetine improves different 
symptoms of ADHD than methylphenidate, and may not be as clinically efficacious in 
some individuals (Cubillo et al, 2014; Faraone et al, 2006). Therefore, it is important to 
  
57	  
identify an alternative stimulant drug, which satisfactorily improves ADHD symptoms 
but does not increase later cocaine abuse risk for teenagers with ADHD.  
 One potential alternative is d-amphetamine (Dexedrine®), a stimulant drug with a 
different mechanism of action than methylphenidate. Amphetamine is more efficacious 
than methylphenidate in relieving ADHD symptoms, and has a similar side effect profile 
(Arnold, 2000; Faraone & Buitelaar, 2010; Patrick & Morowitz, 1997; Sibley et al, 
2014). Formulations of amphetamine often contain both d- and l-isomers. However, the l-
isomer is not prescribed alone, and the d-isomer is more potent in mediating dopamine 
transmission and more efficacious in alleviating ADHD symptoms (Arnold et al, 1973; 
Heal et al 2012, 2013; Patrick & Markowitz 1997). Therefore, d-amphetamine is the 
focus of Aim 2.  
 Although both methylphenidate and d-amphetamine block DAT and NET, d-
amphetamine also reverses activity at these transporters (Robertson et al, 2009). d-
Amphetamine can additionally be taken up into the pre-synaptic terminal, where it 
reverses activity at vesicular monoamine transporter-2 (VMAT-2). Reversal of VMAT-2 
prevents the sequestration and retention of monoamines within vesicles (Easton et al, 
2007). Excess cytosolic monoamines subsequently accumulate, and are transported to the 
extracellular space through reversed activity at DAT and NET (Easton et al, 2007). 
Because of these additional mechanisms of action, d-amphetamine induces greater 
increases in extracellular monoamines than methylphenidate, even at therapeutically 
relevant doses (Kuczenski & Segal, 2001). Another mechanism of action exhibited by d-
amphetamine, which is not shared with methylphenidate, is the ability to bind to the 
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intracellular trace amine-associated receptor 1 (TAAR1). TAAR1 is co-expressed with 
DAT in reward-associated regions, such as the substantia nigra, VTA, and amygdala 
(Lindemann et al, 2008; Xie et al, 2007). Activation of TAAR1 by amphetamine reduces 
cell surface expression of DAT, and may lead to decreased DAT function in reward-
associated regions, such as the striatum (Miller, 2011; Xie & Miller, 2009). Thus, 
whereas adolescent methylphenidate treatment increases DAT function in mPFC of SHR 
and increases cocaine abuse risk (Somkuwar et al, 2013b), adolescent d-amphetamine 
treatment may reduce DAT expression and function. Adolescent d-amphetamine may 
therefore have long-term consequences for cocaine abuse risk that are different from 
methylphenidate. 
 In order to establish the SHR as a viable model for adolescent d-amphetamine 
treatment, it is first necessary to determine whether d-amphetamine improves ADHD-
related deficits in SHR, as it does clinically. In adult SHR, d-amphetamine reduces 
hyperactivity and impulsivity, and improves sustained attention and short- and long-term 
memory (Meneses et al, 2011; Sagvolden & Xu, 2008). However, the effects of d-
amphetamine in adolescent SHR are not well known. As discussed in Chapter One, the 
adolescent brain undergoes unique neurochemical changes, including altered expression 
of dopamine D1 receptors and DAT (Andersen, 2005; Brenhouse et al, 2008; Moll et al, 
2000; Stanis & Andersen, 2014). These observations suggest that psychostimulants may 
differentially affect adolescents, relative to juveniles or adults. Experiment 5 therefore 
determines the effects of d-amphetamine treatment in adolescent WKY, WIS, and SHR, 
on PFC functioning using the strategy set shifting task (Floresco et al, 2008; Harvey et al, 
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2013). Previous studies using this task showed that adolescent SHR exhibit deficits in 
behavioral flexibility during the set shift phase, which is dependent on mPFC functioning 
(Birrell & Brown 2000; Floresco et al, 2008; Harvey et al, 2013; Ragozzino et al, 1999). 
During the set shift phase, atomoxetine improved performance in adolescent SHR 
(Harvey et al 2013). In contrast, methylphenidate improved performance in adolescent 
SHR during initial set formation (Harvey et al, 2013), a phase of the task that is 
dependent on catecholamine projections to PFC as a whole (Crofts et al, 2001). Neither 
drug in adolescent SHR improved reversal learning performance (Harvey et al, 2013), 
which is dependent on OFC functioning (Ghods-Sharifi et al, 2008). Interestingly, these 
findings are consistent with clinical observations that not all ADHD symptoms are 
sufficiently alleviated by single drug therapies (Wilens et al, 2009). Use of the strategy 
set shifting task in Experiment 5 therefore allows differentiation of the effects of d-
amphetamine from those of methylphenidate and atomoxetine on PFC functioning in 
adolescent SHR.  
 If d-amphetamine improves ADHD-related cognitive deficits in adolescent SHR, 
it then becomes important to determine whether adolescent d-amphetamine treatment 
alters cocaine abuse risk in adulthood. Experiments 6 through 8 examined whether 
adolescent d-amphetamine treatment increases cocaine abuse risk in the SHR model. The 
speed to acquire cocaine self-administration, as well as the efficacy and motivating 
influence of cocaine reinforcement, were assessed in adult WKY, WIS, and SHR 
following discontinuation of adolescent treatment with a clinically relevant dose of d-
amphetamine. Fixed-ratio (FR) and progressive ratio (PR) dose-response curves were 
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evaluated using multiple test doses of cocaine, in order to fully characterize cocaine’s 
reinforcing effects and to be directly comparable to Aim 1. 
 Lastly, as reviewed in Chapter Two, another important aspect of cocaine abuse is 
reactivity to cocaine-related cues. The results of Experiment 4 show that SHR are more 
reactive to cocaine cues than control strains. Importantly, the environmental cues 
associated with cocaine use trigger neural activity and dopamine release in regions of the 
brain that are dysfunctional in SHR and in ADHD patients, including the mPFC and OFC 
(Ciccocioppo et al, 2001; Cubillo et al, 2011; Harvey et al, 2013; Jasinka et al, 2014; 
Nelissen et al, 2012; Wilcox et al, 2011). Repeated administration of a clinically relevant 
dose of amphetamine during early adolescence (P22 - 34) in outbred rats was shown to 
increase dendritic length, branching, and spine density in the mPFC (Heijtz et al, 2003). 
If adolescent d-amphetamine treatment induces long-term structural changes in PFC of 
SHR, it is possible that d-amphetamine may also modulate cocaine cue reactivity in this 
strain. Experiment 9 evaluated this possibility by examining cocaine cue reactivity and 
relapse behavior in adult SHR, WKY and WIS, following discontinuation of adolescent 
d-amphetamine treatment. To be directly comparable to Aim 1, a second-order schedule 
of cocaine delivery and cue presentation was used. Cocaine-seeking behavior was 
therefore measured during maintenance testing (cocaine available for self-administration) 
and reinstatement testing (cocaine not available for self-administration).   
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Experiment 5: Effects of d-Amphetamine on Strategy Set Shifting in Adolescent 
Rats  
 
 Experiment 5 tested the hypothesis that adolescent SHR exhibit deficits in 
behavioral flexibility during the strategy set shifting task (e.g., requiring more trials and 
time to reach learning criterion) compared to adolescent WKY and WIS control strains. 
Experiment 5 also tested the hypothesis that adolescent SHR treated with a clinically 
relevant dose of d-amphetamine show improved performance during one or more phases 
of the strategy set shifting task, compared to vehicle-treated SHR.   
 
Materials and Methods 
 Animals and Treatments. All procedures were approved by the Institutional 
Animal Care and Use Committee at Boston University, and were performed in 
accordance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals (Eighth Edition). Male WKY/Cr, WIS/Cr, and SHR/Cr rats (Charles 
River Laboratories, Wilmington, MA, Kingston, NY or Raleigh, NC) arrived on P25. 
Group sizes for Experiment 5 were n = 9 for vehicle and d-amphetamine-treated WKY 
and WIS, n = 10 for vehicle-treated SHR, and n = 12 for d-amphetamine-treated SHR. 
See Figure 17 for an experimental timeline. 
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 Animal housing conditions were identical to those described in Experiment 1. 
From P28 through P55, constituting the rat adolescent period (Spear, 2000), animals 
received once daily i.p. injections of either a clinically relevant dose of d-amphetamine 
(0.5 mg/kg, Sigma-Aldrich, St. Louis, MO) dissolved in 0.9% sterile saline, or saline 
alone (2 ml/kg). The double injection volume was used to be consistent with Experiments 
1 through 4. Treatments were administered once daily, Monday-Friday. The selected dose 
of d-amphetamine produces plasma drug concentrations within the clinical range and is 
below the threshold for causing locomotor activation (Brown et al, 1979; Heitjz et al, 
2003; Labonte et al, 2011). The chosen dose of d-amphetamine also increases dopamine 
and norepinephrine activity and induces long-term structural changes in the PFC (Heijtz 
et al, 2003; Kuczenski & Segal, 2001; Labonte et al, 2011). Treatments were 
administered 30 minutes prior to behavioral testing in the strategy set shifting task, to 
allow peak monoamine responses to occur and to ensure that plasma levels reached 
clinical significance during testing (Heijtz et al, 2003; Kuczenski & Segal, 2001).  Food 
 
Figure 17. Timeline of experimental events in Aim 2. 
  
63	  
was restricted from P28-P55 to ~90% of a growth-adjusted free-feeding body weight, to 
facilitate lever responding for food reinforcement during the set shifting task, and to 
mimic conditions of past comparator studies (Harvey et al, 2011; 2013; Somkuwar et al 
2013a, b). Animals had free access to water throughout the experiment, and food was 
freely available after P55.  
 
 Testing Environment. Experimental chambers were identical to those described in 
Experiment 1, except that response levers were retractable (as in Harvey et al, 2013).  
Pellet dispensers for food delivery were also located inside the cubicle enclosing each 
operant chamber (Med Associates).  
 
 Habituation Training. An operant version of the strategy set shifting task was 
used (Floresco et al, 2008; Harvey et al, 2013). On P28, all animals received 20 
chocolate-flavored pellets in their home cages, to habituate rats to the novel food. On 
P31, all rats began training in experimental chambers. Rats were required to lever press 
under a FR1 schedule to earn a minimum of 25 chocolate pellet reinforcers within a 30-
min period. Thereafter, rats began lever retraction training, requiring a response within 
10-sec of lever insertion into the chamber to earn a chocolate pellet reinforcer. Once rats 
made fewer than 5 omissions for four consecutive 45-min daily sessions, lever position 
bias was established by allowing rats to freely press either lever for ~10-min. The lever 
on which the most responses were made was defined as preferred.   
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 Experiment 5a: Initial Set Formation. On P42, rats were required to adopt a 
visual-based strategy to earn reinforcement. All set shift test sessions were 2 hours in 
length, and were conducted during the light phase once daily, Monday - Friday, at 
approximately the same time each day. During the initial set formation, each trial began 
with a 20-sec timeout in a dark chamber. After 20 sec, one of the two stimulus lights was 
illuminated (randomly selected for each trial). The house light illuminated 3-sec later, and 
both response levers were inserted into the chamber. Rats were required to press the lever 
under the illuminated stimulus light, regardless of lever bias, to earn a chocolate pellet 
reinforcer (see Figure 18). Levers were retracted after a response was made (whether 
correct or incorrect), or if 10-sec elapsed with no response (omission). After a correct 
response, the stimulus light remained illuminated for an additional 4 sec, and a chocolate 
pellet was delivered 15 sec later. The house light remained illuminated until 4 sec after 
pellet delivery. A 15-sec delay to reinforcement was imposed to increase cognitive 
demand and to better detect strain and treatment differences, as SHR are more sensitive 
to delayed reinforcers than WKY (Harvey et al, 2013; Johansen et al, 2005). After an 
incorrect response or a trial omission, the stimulus and house lights were immediately 
extinguished and a new trial was initiated. Training on the initial set formation continued 
until criterion was reached, defined as making 8 consecutive correct responses, following 
Floresco et al, 2008, and Harvey et al, 2013. 
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 Experiment 5b: Set Shift. On the day following completion of the initial set 
formation, rats were required to shift responding to a spatial-based discrimination 
strategy. During this phase, animals were required to press the lever opposite the lever 
position bias to earn reinforcement, regardless of which stimulus light was illuminated 
(see Figure 19). Trial contingencies were otherwise identical to the initial set formation. 
Training on the set shift phase continued until rats made 10 consecutive correct responses 
(Floresco et al, 2008; Harvey et al, 2013). 
 
 
 
Figure 18. Initial set formation requires pressing the lever under the illuminated cue 
light (visual cue discrimination). Adapted from Floresco et al, 2008. 
 
Figure 19. The set shift requires pressing the lever opposite from the preferred lever 
(response discrimination). Adapted from Floresco et al, 2008. 
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 Experiment 5c: Reversal Learning. On the day following completion of the set 
shift phase, reversal learning was assessed. During this final phase of the task, rats were 
required to press the lever on the same side as the lever position bias, regardless of which 
stimulus light was illuminated (see Figure 20). Trial contingencies were otherwise 
identical to those of the initial set and set shift phases. Training on reversal learning 
continued until rats made 10 consecutive correct responses (Floresco et al, 2008; Harvey 
et al, 2013).  
 
 
 Data Analysis. Dependent measures for the strategy set shifting task included 
number of trials completed to reach criterion, latency to reach criterion (included the time 
for omitted trials), number of omitted trials, average lever press reaction time, variability 
in lever press reaction time, and ratio of correct to incorrect lever responses (choice 
accuracy), until criterion was reached. In addition, error subtypes were coded for the set 
shift and reversal learning phases of the task (Harvey et al, 2013; Floresco et al, 2008). 
During the set shift phase, perseverative and regressive errors were recorded when rats 
 
Figure 20. Reversal learning requires pressing the preferred lever (response reversal). 
Adapted from Floresco et al, 2008. 
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pressed a lever with the stimulus light illuminated above it on trials that required pressing 
of the opposite lever. Errors were perseverative when rats pressed the incorrect lever on 
six or more trials per block of eight trials. Once rats made five or fewer incorrect choices 
in a block of eight trials for the first time, the incorrect lever choices in subsequent blocks 
were scored as regressive errors. Never-reinforced errors were recorded when a rat 
pressed the incorrect lever on trials when the correct lever had the stimulus light 
illuminated above it (i.e., a choice that was not reinforced during either the initial set or 
set shift phase). During the reversal-learning phase, errors were examined in blocks of 16 
trials and consisted of perseverative and regressive errors (Ghods-Sharifi et al, 2008; 
Harvey et al, 2013). Once rats made ten or fewer incorrect choices in a block of 16 trials 
for the first time, the incorrect lever choices in subsequent blocks were then scored as 
regressive errors. Never-reinforced errors are not possible during the reversal-learning 
phase. Perseverative errors are an index of how well the previously acquired strategy is 
suppressed, regressive errors are an index of how well the new strategy is maintained, 
and never-reinforced errors are an index of how well the new strategy is acquired 
(Floresco et al, 2008). Measures of the strategy set shifting task were square root 
transformed prior to analysis due to non-normality in the majority of measures. Measures 
were analyzed by two-factor (strain X treatment) ANOVAs, followed by post-hoc Tukey 
tests.   
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Results 
 Experiment 5a: Initial Set Formation. Figure 21 depicts data obtained during the 
initial set formation phase of the strategy set shifting task. Strains differed in trials to 
criterion (F (2, 52) = 5.4, p ≤ 0.008), latency to criterion (F (2, 52) = 5.3, p ≤ 0.008), trial 
omissions (F (2, 52) = 4.5, p ≤ 0.01), average reaction time (F (2, 52) = 9.2, p ≤ 0.001), 
and reaction time variability (F (2, 52) = 9.3, p ≤ 0.001). No strain differences were 
observed for choice accuracy. Adolescent SHR and the WIS control required fewer trials 
to reach criterion (p ≤ 0.01 and 0.02, respectively) and had shorter latencies to reach 
criterion (p ≤ 0.01 and 0.03, respectively) than the WKY control. Both SHR and the 
WKY control exhibited slower reaction time and greater reaction time variability than the 
WIS control (p ≤ 0.01). The WKY control also made more trial omissions than the WIS 
control (p ≤ 0.01). d-Amphetamine treatment did not alter performance on any measure 
across strains during initial set formation.  
 
 Experiment 5b: Set Shift. Figure 22 depicts data obtained during the set shift 
phase of the strategy set shifting task. Strains differed in trials to criterion (F (2, 52) = 
4.8, p ≤ 0.01), latency to criterion (F (2, 52) = 6.4, p ≤ 0.003), trial omissions (F (2, 52) = 
3.7, p ≤ 0.03), average reaction time (F (2, 52) = 3.7, p ≤ 0.03), and reaction time 
variability (F (2, 52) = 8.7, p ≤ 0.001). No strain differences were observed for choice 
accuracy. Adolescent SHR and the WIS control required more trials to reach criterion (ps 
≤ 0.02) and had longer latencies to reach criterion (p ≤ 0.009 and 0.008, respectively) 
than the WKY control. Adolescent SHR also exhibited greater reaction time variability 
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compared to the WKY and WIS controls (p ≤ 0.001 and 0.04, respectively). Moreover, 
SHR exhibited slower reaction times (p ≤ 0.02) and made more omissions (p ≤ 0.03) than 
the WKY control.  
 For latency to criterion, there was a trend towards a strain X treatment interaction 
(F (2, 52) = 2.7, p ≤ 0.07) and further testing revealed that vehicle-treated WKY took less 
time to reach criterion than vehicle-treated WIS and SHR (p ≤ 0.01 and 0.001, 
respectively). d-Amphetamine treatment reduced latency to criterion in adolescent SHR 
only (p ≤ 0.01). There was also a trend towards a strain X treatment interaction (F (2, 52) 
= 2.7, p ≤ 0.07) for choice accuracy, which improved relative to vehicle following d-
amphetamine treatment in adolescent SHR (p ≤ 0.01).  
 
  
70	  
 
 
Figure 21. Trials to criterion, latency to criterion, trial omissions, lever press reaction 
time, variability in reaction time, and choice accuracy during initial set formation in 
adolescent WKY, WIS, and SHR following vehicle or d-amphetamine treatment 
(Mean ± SEM).  & p ≤ 0.05 compared to WKY overall. # p ≤  0.05 compared to WIS 
overall.   
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 Moreover, although the strain X treatment interaction was not significant, further 
testing revealed that d-amphetamine treatment reduced the number of trials required to 
reach criterion in SHR compared to vehicle treatment (p ≤ 0.04).  
 With respect to regressive errors, there was a significant strain X treatment 
interaction (F (2, 52) = 3.3, p ≤ 0.04). Vehicle-treated SHR made more regressive errors 
than vehicle-treated WKY (p ≤ 0.01). Compared to vehicle treatment, d-amphetamine 
reduced regressive errors in SHR only (p ≤ 0.006). For never-reinforced errors, both 
strain (F (2, 52) = 4.6, p ≤ 0.01) and treatment (F (1, 52) = 3.9, p ≤ 0.05) effects were 
observed. Overall, the WIS control made more never-reinforced errors than the WKY 
control (p ≤ 0.01). In addition, rats treated with d-amphetamine made fewer never-
reinforced errors than vehicle-treated rats overall (p ≤ 0.05). Although the strain X 
treatment interaction was not significant, further testing revealed that SHR treated with d-
amphetamine made fewer never-reinforced errors than vehicle-treated SHR (p ≤ 0.04). 
No strain or treatment differences were observed for perseverative errors during the set 
shift phase. 
 
 Experiment 5c: Reversal Learning. Figure 23 depicts data obtained during the 
reversal learning phase of the strategy set shifting task. Strain differences were observed 
in trials to criterion (F (2, 52) = 3.8, p ≤ 0.03), latency to criterion (F (2, 52) = 5.1, p ≤ 
0.01), trial omissions (F (2, 52) = 4.7, p ≤ 0.01), average reaction time (F (2, 52) = 5.6, p 
≤ 0.006), and reaction time variability (F (2, 52) = 6.4, p ≤ 0.003). No strain differences 
were observed for choice accuracy.  
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Figure 22. Trials to criterion, latency to criterion, trial omissions, lever press reaction 
time, variability in reaction time, choice accuracy, and error subtypes during the set 
shift phase in adolescent WKY, WIS, and SHR following vehicle or d-amphetamine 
treatment (Mean ± SEM). * p ≤ 0.05 compared to both other strains. & p ≤ 0.05 
compared to WKY overall. # p ≤  0.05 compared to WIS overall. + p ≤ 0.05 compared 
to vehicle treatment in both other strains. $ p ≤ 0.05 compared to vehicle-treated 
WKY. ^ p ≤ 0.05 compared to vehicle-treated SHR.  
 
 
 Overall, adolescent SHR required fewer trials to reach the reversal learning  
criterion than the WIS control (p ≤ 0.02). Both the WKY control and SHR had shorter 
latencies to reach criterion than the WIS control (p ≤ 0.01 and 0.03, respectively). 
Adolescent WKY also made fewer trial omissions than the WIS control (p ≤ 0.01). SHR 
exhibited slower and more variable reaction times than the WKY control (p ≤ 0.005 and 
0.003, respectively).  
 For perseverative errors, there was a trend towards a main effect of strain (F (2, 
52) = 2.9, p ≤ 0.06). Further testing revealed that SHR made fewer perseverative errors 
than the WIS control (p ≤ 0.05). No strain differences were observed for regressive 
errors. d-Amphetamine treatment did not alter performance on any measure across strains 
during the reversal learning phase. 
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Figure 23. Trials to criterion, latency to criterion, trial omissions, lever press reaction 
time, variability in reaction time, choice accuracy, and error subtypes during the 
reversal learning phase in adolescent WKY, WIS, and SHR following vehicle or d-
amphetamine treatment (Mean ± SEM). & p ≤ compared to WKY overall. # p ≤  0.05 
compared to WIS overall. 
 
 
Experiment 6: Acquisition of Cocaine Self-Administration Following Adolescent d-
Amphetamine Treatment 
 
 Experiment 6 sought to reproduce findings from Experiment 1, showing that adult 
SHR acquire cocaine self-administration faster, earn more cocaine infusions and make 
more lever responses compared to WKY and WIS control strains. Experiment 6 also 
tested the hypothesis that, in contrast to methylphenidate, treatment with a clinically 
relevant dose of d-amphetamine during adolescence does not increase the speed to 
acquire cocaine self-administration in adult SHR after adolescent treatment is 
discontinued. 
 
Materials and Methods 
 New groups of SHR, WKY, and WIS were used in Experiment 6. Rats were 
treated with a clinically relevant dose of d-amphetamine, or saline alone, during 
adolescence, as described in Experiment 5. Group sizes for Experiment 6 were n = 8 per 
strain and treatment group.   
 Surgical procedures, testing environments, cocaine delivery and cocaine self-
administration procedures were identical to those detailed in Experiment 1. Briefly, after 
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recovery from surgical implantation of i.v. catheters, animals were allowed to 
spontaneously acquire cocaine self-administration under a FR1 schedule of 
reinforcement. Training continued until acquisition criterion was reached, defined as 
earning ≥ 20 infusions for two consecutive sessions, and discriminating the active from 
inactive lever by a factor of 2 or greater. All rats reached acquisition criterion in 25 
sessions or less.  
 
 Data Analysis. Dependent measures in Experiment 6 included the number of 
sessions required to reach acquisition criterion (square root transformed prior to analysis 
due to non-normality), as well as cocaine infusions earned and active and inactive lever 
responses at acquisition criterion. Measures were analyzed by two-factor (strain X 
treatment) ANOVAs followed by post-hoc Tukey tests. 
 
Results 
 The number of sessions required to reach acquisition criterion are shown in Figure 
24. Strains differed significantly (F (2, 42) = 14.7, p ≤ 0.001), and there was also a strain 
X treatment interaction (F (2, 42) = 6.6, p ≤ 0.003). Vehicle and d-amphetamine-treated 
SHR acquired cocaine self-administration faster than vehicle- and d-amphetamine-treated 
WKY and WIS (ps ≤ 0.03). Adolescent d-amphetamine slowed acquisition in adult WIS 
(p ≤ 0.004), but speeded acquisition in adult WKY (p ≤ 0.04). d-Amphetamine did not 
alter acquisition speed in SHR. 
  
77	  
 
 
 The number of cocaine infusions earned at the acquisition criterion is shown in 
Figure 25. Differences in strain (F (2, 42) = 16.4, p ≤ 0.001) and treatment (F (2, 42) = 
9.1, p ≤ 0.004) were observed, as well as a trend towards a strain X treatment interaction 
(F (2, 42) = 2.7, p ≤ 0.08). Overall, SHR earned more cocaine infusions than WKY and 
WIS (p ≤ 0.001 and 0.03, respectively). WIS also earned more infusions than WKY (p ≤ 
0.008). Moreover, d-amphetamine-treated rats earned fewer infusions than vehicle-
treated rats (p ≤ 0.005). This effect was driven primarily by reduced cocaine intake in d-
amphetamine-treated WIS and SHR compared to their vehicle counterparts (p ≤ 0.008 
and 0.01, respectively). Adolescent d-amphetamine did not alter cocaine intake in adult 
WKY. 
 
Figure 24. Number of sessions required to reach acquisition criterion in adult WKY, 
WIS, and SHR, following vehicle or d-amphetamine treatment during adolescence 
(Mean ± SEM). * p ≤ 0.05 compared to both other strains. ^ p ≤ 0.05 compared to 
vehicle treatment in the same strain.  
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 Active lever responses at the acquisition criterion are shown in Figure 26. Strains 
(F (2, 42) = 10.5, p ≤ 0.001) and treatments (F (1, 42) = 6.2, p ≤ 0.01) again differed. 
There was also a trend towards a strain X treatment interaction (F (2, 42) = 2.6, p ≤ 0.08). 
Overall, SHR made more active lever responses than WKY and WIS (p ≤ 0.001 and 0.01, 
respectively). d-Amphetamine-treated rats made fewer active lever responses than VEH-
treated rats (p ≤ 0.01). This effect was driven primarily by reduced active lever 
responding in d-amphetamine-treated SHR relative to vehicle-treated SHR (p ≤ 0.004). 
Adolescent d-amphetamine did not significantly alter active lever responding at 
acquisition in adult WKY or WIS. There was also a strain difference in inactive lever 
responding at criterion (F (2, 42) = 3.8, p ≤ 0.03), with SHR making made more inactive 
lever responses (10.4 ± 3.4) than WKY (3.1 ± 0.6; p ≤ 0.05). However, all strains 
 
Figure 25. Number of cocaine infusions earned at acquisition criterion in adult WKY, 
WIS, and SHR, following vehicle or d-amphetamine treatment during adolescence 
(Mean ± SEM). * p ≤ 0.05 compared to both other strains. & p ≤ 0.05 compared to 
WKY overall. ^ p ≤ 0.05 compared to vehicle treatment in the same strain.  
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discriminated the active from the inactive lever by a factor of 2 or greater (10:1 for 
WKY, 16:1 for WIS, and 9:1 for SHR, on average). 
 
 
Experiment 7: Fixed-Ratio Cocaine Dose-Response Functions in Adulthood 
Following Adolescent d-Amphetamine Treatment 
 
 Experiment 7 sought to reproduce findings in Experiment 2, showing that the 
efficacy of cocaine reinforcement is elevated in adult SHR compared to WKY or WIS, 
such that SHR earn more cocaine infusions and make active lever responses across a 
range of doses under a FR1 schedule of reinforcement. Experiment 7 also tested the 
hypothesis that, in contrast to the effects of methylphenidate, treatment with a clinically 
 
Figure 26. Number of active lever responses made at acquisition criterion in adult 
WKY, WIS, and SHR, following vehicle or d-amphetamine treatment during 
adolescence (Mean ± SEM). * p ≤ 0.05 compared to both other strains. ^ p ≤ 0.05 
compared to vehicle treatment in the same strain.  
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relevant dose of d-amphetamine during adolescence does not increase the efficacy of 
cocaine reinforcement in adult SHR after adolescent treatment is discontinued. 
 
Materials and Methods 
 Cocaine self-administration procedures in Experiment 7 were identical to those 
detailed in Experiment 2. Briefly, following achievement of acquisition criterion in 
Experiment 6, a stable baseline level of responding for the 0.3 mg/kg training dose was 
established in all animals. A range of cocaine doses (0.003 to 1.0 mg/kg/infusion) was 
then substituted in pseudo-random order, every Tuesday and Friday. The 0.3 mg/kg 
training dose was available on intervening days, and for 2-3 days following completion of 
full FR1 cocaine dose-response functions. One vehicle- and one d-amphetamine-treated 
SHR expired prior to completing Experiment 7, and were therefore excluded from 
Experiment 7 data analyses.  
 
 Data Analysis. Dependent measures for Experiment 7 included the number of 
cocaine infusions earned, and active and inactive lever responses for each cocaine dose. 
Measures were analyzed by three-factor (strain X treatment X dose) ANOVAs, with 
repeated measures for dose followed by post-hoc Tukey tests. 
 
Results 
 Cocaine dose-response functions based on the number of infusions earned under 
the FR1 schedule are shown in Figure 27. Three-way ANOVA identified differences in 
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strain (F (2, 40) = 36.3, p ≤ 0.001) and dose (F (5, 200) = 87, p ≤ 0.001). There were also 
interactions for strain X treatment (F (2, 40) = 3.9, p ≤ 0.03), strain X dose (F (10, 200) = 
8, p ≤ 0.001), and strain X treatment X dose (F (10, 200) = 2.5, p ≤ 0.007). Overall, SHR 
earned more infusions than WKY and WIS at 0.003, 0.01, 0.03, and 0.1 mg/kg cocaine 
(ps ≤ 0.001), and more infusions than WKY at 0.3 mg/kg cocaine (p ≤ 0.006). WIS 
earned more infusions than WKY at 0.1 mg/kg cocaine (p ≤ 0.004). Adolescent d-
amphetamine reduced intake at 0.1 and 0.3 mg/kg cocaine in adult WIS (p ≤ 0.001 and 
0.01, respectively), and did not alter intake in adult WKY or SHR.  
 
 
 
Figure 27. Cocaine dose-response functions based on infusions earned under a FR1 
schedule of reinforcement by adult WKY, WIS, and SHR, following vehicle or d-
amphetamine treatment during adolescence (Mean ± SEM). * p ≤ 0.05 compared to 
both other strains.  § p ≤ 0.05 compared, overall, to the same dose in WKY. ^ p ≤ 
0.05 compared to vehicle treatment in the same strain.  
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 Analyses of the cocaine dose-response functions based on the number of active 
lever responses (Figure 28) were similar to the infusions analysis. For the three-way 
ANOVA, differences in strain (F (2, 40) = 30.1, p ≤ 0.001) and dose (F (5, 200) = 50.3, p 
≤ 0.001) were observed. There was also a strain X dose interaction (F (10, 200) = 7.1, p ≤ 
0.001), and a trend towards a strain X treatment interaction (F (2, 40) = 2.8, p ≤ 0.07). 
SHR made more active lever responses than WKY and WIS for 0.003, 0.01, 0.03, and 0.1 
mg/kg cocaine (ps ≤ 0.001). Adolescent d-amphetamine treatment reduced active lever 
responses for 0.1 and 0.3 mg/kg cocaine in adult WIS (p ≤ 0.001 and 0.05, respectively), 
and did not alter active responses in adult WKY or SHR. Analysis of inactive responding 
during FR1 dose-response testing also revealed a strain difference (F (2, 40) = 4.3, p ≤ 
0.02). SHR made more inactive responses (59.1 ± 16.7) than WKY (9.6 ± 1; p ≤ 0.02).  
 
 
Figure 28. Cocaine dose-response functions based on active lever responses made 
under a FR1 schedule of reinforcement by adult WKY, WIS, and SHR, following 
vehicle or d-amphetamine treatment during adolescence (Mean ± SEM). * p ≤ 0.05 
compared to both other strains.  § p ≤ 0.05 compared, overall, to the same dose in 
WKY. ^ p ≤ 0.05 compared to vehicle treatment in the same strain.  
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Experiment 8: Progressive-Ratio Cocaine Dose-Response Functions in Adulthood 
Following Adolescent d-Amphetamine Treatment 
 
  Experiment 8 sought to reproduce findings of Experiment 3, showing that the 
motivating influence of cocaine reinforcement is elevated in adult SHR compared to 
WKY or WIS, such that SHR work harder to earn cocaine reinforcement, earn more 
cocaine infusions and make more active lever responses across a range of doses under a 
PR schedule. Experiment 8 also tested the hypothesis that, in contrast to the effects of 
methylphenidate, treatment with a clinically relevant dose of d-amphetamine during 
adolescence does not increase the efficacy of cocaine reinforcement in adult SHR after 
adolescent treatment is discontinued. 
 
Materials and Methods 
 Cocaine self-administration procedures in Experiment 8 were identical to those 
detailed in Experiment 3. Briefly, after rats returned to baseline levels of responding for 
0.3 mg/kg cocaine on the FR1 schedule in Experiment 7, a PR schedule of reinforcement 
was instituted. This schedule required rats to press the active lever an incrementally 
greater number of times to earn each subsequent cocaine infusion. In Experiment 8, self-
administration sessions were terminated when rats failed to reach the next response 
requirement within 1 hour or after 4.5 hours had elapsed, which ever occurred first. After 
stable levels of responding for 0.3 mg/kg were established under the PR schedule, 
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cocaine test doses (0.01 - 1.0 mg/kg) were substituted in descending order, with 2-3 
consecutive sessions allocated to each dose. Baseline responding was reestablished for 
0.3 mg/kg cocaine after the full PR dose-response function was completed. One vehicle- 
and one d-amphetamine-treated WKY and an additional d-amphetamine-treated SHR 
expired prior to completing Experiment 8, and were thus excluded from Experiment 8 
data analyses. At the end of Experiment 8, animals were humanely euthanized with an 
overdose of sodium pentobarbital (Euthasol).  
 
 Data Analysis. Dependent measures for Experiment 8 included PR breakpoints, 
the number of cocaine infusions earned, and active and inactive lever responses for each 
cocaine dose. Measures were analyzed by three-factor (strain X treatment X dose) 
ANOVAs, with repeated measures for dose, followed by post-hoc Tukey tests. 
 
Results 
 Cocaine dose-response functions based on the PR breakpoint are shown in Figure 
29. Three-way ANOVA identified differences in strain (F (2, 37) = 42.6, p ≤ 0.001) and 
dose (F (3, 111) = 71.6, p ≤ 0.001). There was also a significant strain X dose interaction 
(F (6, 111) = 6.5, p ≤ 0.001) and a trend towards a treatment difference (F (1, 37) = 3.2, p 
≤ 0.08). SHR reached higher breakpoints than WKY and WIS across all cocaine doses 
(ps ≤ 0.001, except for 0.01 mg/kg where ps ≤ 0.05). Adolescent d-amphetamine 
treatment reduced PR breakpoints in adult WIS at 0.3 and 1.0 mg/kg cocaine (p ≤ 0.05 
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and 0.001, respectively), and did not significantly alter PR breakpoints in adult WKY or 
SHR.  
 
 
 The PR cocaine dose-response functions based on the number of cocaine 
infusions earned are shown in Figure 30. Three-way ANOVA revealed differences in 
strain (F (2, 37) = 43.6, p ≤ 0.001), treatment (F (1, 37) = 5.8, p ≤ 0.02), and dose (F (3, 
111) = 120.4, p ≤ 0.001). There was also a treatment X dose (F (3, 111) = 3.4, p ≤ 0.02) 
and strain X treatment X dose (F (6, 111) = 2.2, p ≤ 0.05) interaction, and a trend towards 
a strain X treatment interaction (F (2, 37) = 2.8, p ≤ 0.07). Overall, SHR earned more 
cocaine infusions than WKY and WIS across all cocaine doses (ps ≤ 0.001). Rats treated 
with d-amphetamine during adolescence earned fewer cocaine infusions than vehicle-
 
Figure 29. Cocaine dose-response functions, based on breakpoints reached under a 
PR schedule of reinforcement, by adult WKY, WIS, and SHR following vehicle or d-
amphetamine treatment during adolescence (Mean ± SEM). * p ≤ 0.05 compared to 
both other strains. ^ p ≤ 0.05 compared to vehicle treatment in the same strain.  
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treated rats at 0.3 and 1.0 mg/kg cocaine (p ≤ 0.05 and 0.01, respectively). More 
specifically, adolescent d-amphetamine reduced cocaine intake in adult WIS at 0.3 and 
1.0 mg/kg cocaine (p ≤ 0.003 and 0.001, respectively), and did not significantly alter 
cocaine intake in adult WKY or SHR.  
 
 
 
 The PR cocaine dose-response functions based on active lever responses are 
shown in Figure 31. For the three-way ANOVA, differences in strain (F (2, 37) = 39, p ≤ 
0.001) and dose (F (3, 111) = 62.7, p ≤ 0.001) were observed, as well as a strain X dose 
interaction (F (6, 111) = 6.3, p ≤ 0.001). SHR made more active lever responses than 
WKY and WIS (all dose ps ≤ 0.001, except for 0.01 mg/kg where ps ≤ 0.06). Rats treated 
 
Figure 30. Cocaine dose-response functions, based on infusions earned under a PR 
schedule of reinforcement, by adult WKY, WIS, and SHR following vehicle or d-
amphetamine treatment during adolescence (Mean ± SEM). * p ≤ 0.05 compared to 
both other strains. ^ p ≤ 0.05 compared to vehicle treatment in the same strain.  
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with d-amphetamine during adolescence made fewer active lever responses than vehicle-
treated rats at 1.0 mg/kg cocaine (p ≤ 0.02). More specifically, adolescent d-amphetamine 
reduced active lever responding in adult WIS at 1.0 mg/kg cocaine (p ≤ 0.001). There 
was also a trend towards reduced active lever responding at 0.3 mg/kg cocaine in d-
amphetamine-treated WIS (p ≤ 0.07). Adolescent d-amphetamine did not alter active 
lever responding in adult WKY or SHR.  
 
 
 For inactive lever responding under the PR schedule, there was a main effect of 
dose (F (3, 111) = 2.6, p ≤ 0.05), although post-hoc testing did not reveal any significant 
differences between cocaine doses. There was also a trend towards a strain difference in 
 
Figure 31. Cocaine dose-response functions, based on active lever responding under 
a PR schedule of reinforcement, by adult WKY, WIS, and SHR following vehicle or 
d-amphetamine treatment during adolescence (Mean ± SEM). * p ≤ 0.05 compared to 
both other strains. ^ p ≤ 0.05 compared to vehicle treatment in the same strain.  
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inactive lever responding (F (2, 37) = 2.8, p ≤ 0.07). Further testing revealed that SHR 
overall made more inactive responses (111.8 ± 48) than WKY (7.8 ± 1.4, p ≤ 0.05).  
 
Experiment 9: Cocaine Cue Reactivity and Relapse Behavior in Adulthood 
Following Adolescent d-Amphetamine Treatment 
 
 Experiment 9 sought to reproduce findings in Experiment 4, showing that adult 
SHR are more reactive to cocaine-related cues than WKY and WIS, such that SHR emit 
more cocaine-seeking responses under a second-order schedule of cocaine delivery and 
cue presentation. Experiment 9 also tested the hypothesis that treatment with a clinically 
relevant dose of d-amphetamine during adolescence does not increase cocaine cue 
reactivity in adult SHR, after adolescent treatment is discontinued.  
 
Materials and Methods 
 Experiment 9a: Maintenance Testing under a Second-Order Schedule. 
Experiment 9 involved animals from Experiment 5, which underwent strategy set shift 
testing and were treated with d-amphetamine or saline during adolescence. Surgical and 
cocaine self-administration procedures were identical to those followed in Experiment 4, 
except that rats in Experiment 9 did not require lever training for food to facilitate 
acquisition of responding, due to prior lever-pressing experience in Experiment 5. 
Briefly, on P67, animals completing Experiment 5 underwent surgical implantation of i.v. 
catheters. On P77, following surgical recovery, rats began self-administration training for 
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0.3 mg/kg cocaine under an FR1 schedule, and were incrementally trained to a terminal 
fixed-interval (FI)-based second-order schedule, designated FI 5-min [FR5:S]. Training 
on the second-order schedule continued until rats reached stable levels of responding, 
designated the maintenance testing phase. Final group sizes for Experiment 9 were n = 8 
for vehicle- and d-amphetamine-treated WKY and WIS as well as for vehicle-treated 
SHR; the group size for d-amphetamine-treated SHR was n = 9.  
 
 Experiment 9b: Extinction Training. Following completion of the maintenance 
testing phase, rats underwent response extinction training as described in Experiment 4b. 
Extinction training continued for a minimum of 10 sessions or until criterion was 
reached, defined as active lever responding that was ≤ 10% of the maintenance baseline 
for 3 consecutive sessions (constituting the extinction baseline). If rats did not reach 
criterion, a maximum of 21 extinction sessions was imposed. 
 
 Experiment 9c: Cue-Induced Reinstatement Testing. Following achievement of 
extinction criterion, rats underwent cue-induced reinstatement testing as described in 
Experiment 4c. All rats underwent 7 reinstatement sessions. At the end of Experiment 9c, 
all animals were humanely euthanized with an overdose of sodium pentobarbital 
(Euthasol). 
 
 Data Analysis. Dependent measures in Experiment 9 included the number of 
cocaine infusions earned, active and inactive lever responses, and the number of sessions 
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required to reach extinction criterion. Measures were analyzed by three-factor (strain X 
treatment X reinstatement session, or strain X treatment X phase) ANOVAs, with 
repeated measures for session or phase (extinction vs. reinstatement), followed by post-
hoc Tukey tests.  
 
Results 
 Experiment 9a: Maintenance Testing under a Second-Order Schedule. Cocaine 
intake during maintenance testing under the second-order schedule is depicted in Figure 
32. Strains differed in cocaine intake (F (2, 43) = 12.3, p ≤ 0.001), with adult SHR 
earning more cocaine infusions than WKY and WIS control strains (p ≤ 0.001 and 0.03, 
respectively). Main and interaction effects of treatment were not significant, and further 
analysis confirmed that adolescent d-amphetamine treatment did not alter cocaine intake 
in any strain during maintenance testing.  
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 Active lever responses during maintenance testing and during the first drug-free 
interval of the final maintenance testing session are shown in Figures 33 and 34, 
respectively. Analysis of active lever responding during maintenance testing revealed 
strain differences (F (2, 43) = 13.6, p ≤ 0.001). Overall, adult SHR made more active 
lever responses than WKY and WIS control strains (p ≤ 0.001 and 0.005, respectively). 
During the first drug-free interval, there was also a main effect of strain (F (2, 43) = 20.2, 
p ≤ 0.001). Adult SHR again made more active lever responses than WKY and WIS 
control (p ≤ 0.005 and 0.001, respectively). Main and interaction effects of treatment 
were not significant. Further analysis additionally confirmed that adolescent d-
amphetamine treatment did not alter cocaine seeking in any strain during maintenance 
testing. Inactive lever responses also did not differ by strain or treatment. 
 
Figure 32. Cocaine intake during maintenance testing under a second-order schedule 
of reinforcement in adult WKY, WIS, and SHR, following vehicle or d-amphetamine 
treatment during adolescence (Mean ± SEM). * p ≤ 0.05 compared to both other 
strains.  
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Figure 33. Active lever responding averaged across the maintenance testing baseline 
in adult WKY, WIS, and SHR, following vehicle or d-amphetamine treatment during 
adolescence (Mean ± SEM). * p ≤ 0.05 compared to both other strains.  
 
Figure 34. Active lever responding during the first drug-free interval of the final 
maintenance testing session in adult WKY, WIS, and SHR, following vehicle or d-
amphetamine treatment during adolescence (Mean ± SEM). * p ≤ 0.05 compared to 
both other strains.  
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 Experiment 9b: Extinction Training. The number of sessions required for rats to 
reach extinction criterion is shown in Figure 35. Strains differed in the number of 
sessions (F (2, 43) = 8.1, p ≤ 0.001), with SHR requiring more sessions to extinguish 
responding than WKY or WIS controls (p ≤ 0.01 and 0.001, respectively). Analysis of the 
extinction baseline (Figure 36) also revealed strain differences (F (2, 43) = 4, p ≤ 0.02). 
SHR and inbred WKY controls made relatively more active lever responses than the 
outbred WIS control strain during the extinction baseline (p ≤ 0.05 and 0.04, 
respectively). However, all strains extinguished to less than 10% of the maintenance 
baseline level of responding. Inactive lever responses during the extinction baseline also 
differed by strain (F (2, 43) = 3.7, p ≤ 0.03), with SHR making more inactive responses 
(31 ± 12) than WIS (6 ± 1; p ≤ 0.03), but not WKY (9 ± 2). Adolescent d-amphetamine 
treatment did not alter any measure across strains during extinction training in adult rats.  
 
 
Figure 35. Number of sessions required to reach extinction criterion in adult WKY, 
WIS, and SHR, following vehicle or d-amphetamine treatment during adolescence 
(Mean ± SEM). * p ≤ 0.05 compared to both other strains.  
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 Experiment 9c: Cue-Induced Reinstatement Testing. The number of active lever 
responses during reinstatement testing, averaged across the seven sessions of testing as 
well as during the first hour of the extinction baseline for comparison, is shown in Figure 
37. Three-way ANOVA revealed a main effect of phase (F (1, 43) = 116, p ≤ 0.001) and 
strain (F (2, 43) = 41.2, p ≤ 0.001), as well as a strain X phase interaction (F (2, 43) = 
19.5, p ≤ 0.001). Post-hoc testing of the interaction indicated that cue re-exposure 
reinstated cocaine-seeking responses above extinction levels in all groups (ps ≤ 0.001). 
Adult SHR reinstated more cocaine-seeking responses than WKY and WIS (ps ≤ 0.001). 
SHR also emitted more responses during the first hour of the extinction baseline than 
WKY and WIS (ps ≤ 0.03). There were no treatment differences in active lever responses 
averaged across the seven sessions of reinstatement testing.  
 
Figure 36. Active lever responding during the extinction baseline, expressed as a 
percentage of the maintenance testing baseline, in adult WKY, WIS, and SHR, 
following vehicle or d-amphetamine treatment during adolescence (Mean ± SEM).    
# p ≤ 0.05 compared to WIS overall. 
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 Effects of d-amphetamine emerged when cocaine-seeking responses were 
analyzed within the seven individual reinstatement test sessions, as shown in Figure 38. 
Three-way ANOVA revealed a main effect of strain (F (2, 42) = 32.8, p ≤ 0.001) and 
reinstatement session (F (6, 252) = 2.5, p ≤ 0.02). Further testing revealed that, during 
session 1 of reinstatement, SHR reinstated more active lever responses than the WKY 
and WIS controls overall (p ≤ 0.001). Moreover, adult SHR treated with adolescent d-
amphetamine reinstated fewer active lever responses than SHR treated with vehicle (p ≤ 
0.003). However, this reduction was not maintained across reinstatement sessions in 
amphetamine-treated SHR. For each subsequent session of reinstatement testing, strain 
differences were sustained (SHR > WKY = WIS; ps ≤ 0.008). In WKY or WIS, 
 
Figure 37. Active lever responding averaged across the seven reinstatement test 
sessions in adult WKY, WIS, and SHR, following vehicle or d-amphetamine 
treatment during adolescence. For comparison, active lever responses during the first 
hour of extinction training were averaged across the extinction baseline and are 
depicted in the gray bars (Mean ± SEM). * p ≤ 0.05 compared to both other strains.  
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adolescent d-amphetamine treatment did not alter active lever responses during session 1 
or on any other reinstatement test session.  
 For inactive lever responses, three-way ANOVA revealed a session X strain X 
treatment interaction (F (12, 252) = 2.2, p ≤ 0.01). Further testing indicated that, overall, 
SHR made more inactive lever responses than the WKY and WIS controls (p ≤ 0.03). 
Moreover, during session 1 of reinstatement, adult SHR treated with adolescent d-
amphetamine made fewer inactive lever responses than SHR treated with vehicle (p ≤ 
0.006). In WKY and WIS, adolescent d-amphetamine treatment did not alter inactive 
lever responses during session 1 or on any other reinstatement test session.  
 
 
 
Figure 38. Active lever responses during each reinstatement test session in adult 
WKY, WIS, and SHR, following vehicle or d-amphetamine treatment during 
adolescence. For comparison, active lever responses during the first hour of 
extinction (Ext) training, averaged across the extinction baseline, are also shown 
(Mean ± SEM). * p ≤ 0.05 compared to both other strains. ^ p ≤ 0.05 compared to 
vehicle treatment in the same strain. 
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Discussion 
 
Strain Differences in Prefrontal Cortex Functioning in Adolescence  
 Experiment 5 employed an operant version of the strategy set-shifting task to 
assess PFC functioning during adolescence in the SHR model of ADHD. During the 
initial set formation, SHR exhibited slower and more variable reaction times than WIS. 
These results are consistent with observations in individuals with ADHD who 
demonstrate high between-subject reaction time variability, and in some studies, slower 
reaction time, compared to controls without ADHD (Kofler et al, 2013). High reaction 
time variability is, moreover, a robust and highly replicable feature of ADHD and may 
contribute to other symptoms, such as poor sustained attention, behavioral inhibition, and 
working memory deficits (Kofler et al, 2013). Interestingly, these symptoms have been 
attributed to altered frontal cortex and DAT functioning (Kofler et al, 2013; MacDonald 
et al, 2006), which also are observed in SHR (Li et al, 2007; Mill et al, 2005; Miller et al, 
2014; Roessner et al, 2010; Watanabe et al, 1997).  
 During the initial set formation, adolescent SHR did not show deficits in speed of 
learning or choice accuracy, or have a greater number of trial omissions relative to WKY 
or WIS, consistent with prior work (Harvey et al, 2013). It is possible that SHR more 
readily respond than WKY or WIS for reinforcement under task conditions that do not 
require complex behavioral flexibility, such as during acquisition of the initial attentional 
set (Harvey et al, 2013; Johansen et al, 2002). However, WKY made more trial omissions 
and had slower and more variable reaction times than WIS, and took longer to reach 
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learning criterion than both WIS and SHR. The latter finding was observed both in the 
current investigation and in prior work (Harvey et al, 2013). Therefore, it is possible that 
adolescent WKY are less proficient in their ability to acquire the initial set relative to the 
other two strains. Although WKY are frequently used as an inbred control strain for SHR 
(Russell et al, 2005), the WKY, particularly from Charles River Laboratories in the USA, 
also have been used as a model of anxiety, depression, and more recently, autism 
spectrum disorder (Paré et al, 1994; Paré & Kluczynski, 1997; Zhang-James et al, 2014). 
Compared to outbred rat strains, WKY show reduced locomotor activity and social 
exploratory behavior in the open field test, elevated plus maze, and three-chamber social 
interaction test, as well as increased learned helplessness and immobility in forced swim 
and defensive burying paradigms (Pardon et al, 2002; Paré et al, 1994; Zhang-James et al, 
2014). Furthermore, in reinforcement-based tasks, WKY earn fewer sucrose pellets than 
WIS under FR1 and PR schedules (De La Garza II, 2005). Behavioral abnormalities 
exhibited by WKY have been attributed to reduced cortical and hippocampal volume and 
plasticity, decreased D1 receptor and DAT binding in striatum, and decreased dopamine 
and dopamine metabolite levels in PFC relative to outbred rat strains (Cominski et al, 
2014; De La Garza II & Mahoney III, 2004; Jiao et al, 2003; Novick et al, 2008). 
Importantly, the initial set formation of the strategy set shifting task is dependent on 
dopaminergic projections to frontal cortex as a whole, as 6-OHDA lesions in frontal 
cortex, but not caudate nucleus, impaired acquisition of an initial set (Crofts et al, 2001). 
Decreased dopamine levels in frontal cortex of WKY (De La Garza II & Mahoney III, 
2004) may therefore contribute to slower learning of the initial strategy set in this strain. 
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Although the WKY have been proposed to be the most appropriate comparator strain for 
SHR (Harvey et al, 2013; Russell et al, 2005), these findings emphasize the importance 
of concurrent evaluation of WKY and an outbred control when examining set shifting 
performance in SHR. 
 In contrast to the initial set formation, the set shift phase of the task necessitates 
behavioral flexibility, requiring rats to switch responding from a previously learned 
visual strategy to a spatial strategy. Consistent with previous studies (Harvey et al, 2013) 
and as hypothesized, adolescent SHR in the current study showed the greatest deficits 
during the set shift phase. Specifically, SHR exhibited slower and more variable reaction 
times, and made more trial omissions and regressive errors than both control strains. On 
the Wisconsin Card Sorting Task, individuals with ADHD exhibit poor behavioral 
flexibility by making more perseverative responses and completing fewer categories than 
typically developing controls (Kado et al, 2012; Reeve & Schandler, 2001; Seidman et al, 
1997). Poor behavioral flexibility and other ADHD-related symptoms, such as 
hyperactivity, inattention, low motivation, and poor motor timing and response inhibition, 
may arise from abnormal neural activation and connectivity in frontostriatal circuitry 
both in humans and in SHR (Cubillo et al, 2012; Rubia et al, 2011; Warton et al, 2009). 
For example, as reviewed in Chapter One, individuals with ADHD exhibit elevated 
frontostriatal glutamate transmission (Courvoisie et al, 2004; MacMaster et al, 2003), and 
SHR exhibit greater potassium-evoked glutamate release in PFC (Miller et al, 2014). 
Moreover, glutamate application to substantia nigra, which receives excitatory 
projections from mPFC, results in greater dopamine release in the substantia nigra of 
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SHR compared to controls (Warton et al, 2009). Elevated dopamine activity in substantia 
nigra and striatum may also contribute to other neurochemical and genetic abnormalities 
shared by SHR and individuals with ADHD. These include increased DAT expression in 
striatum (Faraone et al, 2005; Mill et al, 2005; Roessner et al, 2010; Watanabe et al, 
1997) and decreased dopamine D4 receptor gene expression and protein synthesis in 
PFC, the latter of which is involved in regulating PFC glutamate activity (Li et al, 2007; 
Miller et al, 2014). Because many studies investigating the neurobiological correlates of 
the ADHD phenotype in SHR have employed WKY as the sole comparator strain, these 
comparisons should be interpreted cautiously. Nonetheless, altered frontostriatal 
glutamate and dopamine activity, among other neurochemical abnormalities, likely 
contribute to poor SHR performance on the set shift. Previous studies have established 
that dopamine and glutamate interactions in mPFC are critical for behavioral flexibility 
and strategy switching (Floresco et al, 2008) and that dopamine and glutamate 
interactions in substantia nigra are critical for initiation of locomotor activity (Warton et 
al, 2009).  
 During the set shift phase, WKY reached learning criterion faster than both WIS 
and SHR and made fewer errors than WIS. It is possible that WKY exhibit superior 
behavioral flexibility in strategy shifting compared to WIS or SHR. However, given that 
WKY were slower in acquiring the initial set, it is also possible that WKY experienced 
less proactive interference during the set shift than WIS or SHR. Proactive interference 
from a previously relevant stimulus dimension exacerbates cognitive inflexibility when 
individuals are required to attend to a new stimulus feature (Dick, 2012). Previous work 
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identified reduced proactive interference in WKY in an eyeblink conditioning paradigm, 
whereby pre-exposure to unconditioned or conditioned stimuli did not alter acquisition 
rate of the eyeblink response in WKY, but slowed acquisition in outbred Sprague-Dawley 
rats (Ricart et al, 2015). Though it is unclear to what degree proactive interference in 
classical conditioning generalizes to operant conditioning, it is plausible that weakened 
acquisition, memory storage, or retrieval of the initially reinforced visual strategy by 
WKY in the current study could lead to reduced proactive interference during subsequent 
testing phases. This would be manifested as fewer errors and an apparently faster ability 
to acquire new response strategies (Kantak et al, 2014).  
 Reduced proactive interference may also help to explain some of the current 
observations during the reversal learning phase of the set shift task. During reversal 
learning, SHR continued to show slower and more variable reaction times, consistent 
with the ADHD phenotype. However, WKY and SHR reached the reversal learning 
criterion faster than WIS. Moreover, during this phase WKY made fewer trial omissions 
and SHR made fewer perseverative errors than WIS rats. It is possible that, relative to 
SHR and WKY, WIS exhibit deficits in reversal learning, which is dependent on OFC 
functioning (Ghods-Sharifi et al, 2008). However, given the behavioral and 
neurobiological abnormalities in WKY and SHR reviewed above, an alternative 
explanation is that WKY and SHR experienced less proactive interference than WIS 
during reversal learning. Deficient learning or memory of the previously acquired 
behavioral strategies by WKY and SHR would lead to the appearance of superior 
performance relative to WIS during the reversal learning phase. Conversely, normative 
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learning and retrieval of the previously acquired behavioral strategy by WIS would lead 
to increased proactive interference, resulting in slower speed of reversal learning and a 
greater number of perseverative errors as observed in the current study.  
 
Effects of d-Amphetamine Treatment on Prefrontal Cortex Functioning in Adolescence 
 As hypothesized, d-amphetamine improved several behavioral measures in 
adolescent SHR during the set shift phase. Specifically, SHR treated with d-amphetamine 
reached the set shift learning criterion faster, were more accurate in response choices, and 
made fewer regressive and never-reinforced errors than vehicle-treated SHR. Although d-
amphetamine did not improve reaction time or reaction time variability in SHR during 
any phase of the set shift task, it is rare that all ADHD symptoms are alleviated by single 
drug therapy (Wilens et al, 2009). It is possible that a higher d-amphetamine dose would 
improve additional ADHD-related deficits in SHR. For example, d-amphetamine doses of 
0.64, 1.27, and 1.91 mg/kg improved hyperactivity and sustained attention in adult SHR, 
but only 1.27 and 1.91 mg/kg of d-amphetamine improved impulsivity in adult SHR 
(Sagvolden & Xu, 2008). However, these higher doses are also likely to produce plasma 
levels and monoamine responses that exceed clinical relevance, in contrast to the 0.5 
mg/kg dose used in the current work (Heijtz et al, 2003). Nonetheless, the current 
findings indicate that d-amphetamine selectively improves behavioral flexibility in SHR 
without altering performance in WKY or WIS control strains.   
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Strain Differences in Cocaine Abuse Risk and Cocaine Cue Reactivity in Adulthood 
 In Experiment 6, adult SHR spontaneously acquired cocaine self-administration 
faster, earned more cocaine infusions, and made more cocaine-maintained responses than 
adult WKY and WIS controls, consistent with the findings in Aim 1. SHR also exhibited 
increased cocaine abuse risk in Experiments 7 and 8, as reflected by vertical (upward) 
shifts in FR1 and PR cocaine dose-response functions. These results indicate that the 
efficacy and motivating influence of cocaine reinforcement is augmented in SHR, in 
accord with the results of Aim 1 and with prior studies (Harvey et al, 2011; Piazza et al, 
2000; Somkuwar et al, 2013a). Moreover, Experiment 9 reproduced findings showing 
that SHR were more reactive to cocaine-related cues than WKY and WIS, both when 
cocaine was available (maintenance testing) and was not available (reinstatement testing) 
for self-administration.  
 One notable difference across experiments is that SHR took longer to extinguish 
lever responding than WKY and WIS in Experiment 9. Conversely, in Experiment 4, 
both SHR and WKY took longer to extinguish lever responding than WIS. The latter 
result was interpreted to suggest that extinction learning was augmented in the WIS 
strain, rather than SHR exhibiting an extinction deficit. However, other studies have 
suggested that, like individuals with ADHD, SHR exhibit slower extinction rates than 
controls (Brackney et al, 2012; Kollins et al, 1997). Moreover, slower extinction in SHR 
may be a result of abnormal nigrostriatal dopamine functioning that conveys low 
sensitivity to changes in reinforcement contingencies, a deficit also found in individuals 
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with ADHD (Kollins et al, 1997; Sagvolden et al, 2005). The findings of Experiment 9, 
in conjunction with prior work, suggest that SHR do exhibit deficits in extinction 
learning. Nonetheless, SHR did not differ from WKY in the relative magnitude to which 
responding was extinguished, and all strains and treatment groups extinguished active 
lever responding to ≤ 10% of the self-administration baselines, on average. High levels of 
cocaine seeking by SHR during reinstatement testing thus remain reflective of heightened 
cocaine cue reactivity in this preclinical model of ADHD.  
 Another notable behavioral difference in Experiment 9 vs. Experiment 4 was that 
both vehicle- and drug-treated rats of WKY, WIS, and SHR strains exhibited lower rates 
of lever responding overall in Experiment 9. This may relate to the fact that the adult rats 
used in Experiment 9 had prior lever training experience during adolescence, and 
exposure to chocolate pellet reinforcers, from engaging in the strategy set shifting task 
(Experiment 5). In contrast, the adult rats used in Experiment 4 were naïve to operant 
chambers and had no lever training experience until adulthood. Interestingly, a similar 
effect was observed in experiments evaluating methylphenidate and atomoxetine 
treatments, wherein adult rats that participated in strategy set shifting during adolescence 
exhibited reduced rates of lever responding in adulthood, compared to rats that were 
naïve to operant chambers until adulthood (Jordan et al, 2014). Together, these findings 
suggest that lever pressing or reinforcer experience during adolescence may influence the 
overall magnitude of responding for cocaine under the second-order schedule. However, 
despite these differences in overall rates of responding, the same relative magnitude of 
strain differences was observed in all experiments. That is, SHR consistently made more 
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cocaine-seeking responses and earned more cocaine infusions than WKY and WIS 
control strains. The fact that these strain differences have been reproduced in multiple 
experiments run at different time points and, in the case of the methylphenidate, by a 
different investigator, indicates that the findings are highly robust, and further 
emphasizes that the SHR is a valuable model of comorbid ADHD, cocaine abuse, and 
heightened cocaine cue reactivity.  
 In addition to elevated cocaine abuse risk and cue reactivity, SHR generally 
exhibited increased inactive lever responding compared to control strains, particularly 
relative to the inbred WKY. Notably, hyperactivity in the SHR has previously been 
criticized as apparent only relative to WKY, which exhibits reduced locomotor activity 
compared to outbred rats in a number of behavioral tests (Kantak et al, 2008; Pardon et 
al, 2002; Paré & Kluczynski, 1997; Zhang-James et al, 2014). However, in the current 
work, WKY and WIS did not differ on any measure of cocaine self-administration, with 
the exception of modest differences during extinction training and responding for cocaine 
under the FR1 schedule. These observations contradict the possibility that WKY 
hypoactivity influenced the current findings. Nonetheless, these findings again emphasize 
the importance of concurrent evaluation of WKY and an outbred control when examining 
set shifting performance in SHR. 
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Effects of Adolescent d-Amphetamine Treatment on Cocaine Abuse Risk and Cue 
Reactivity in Adulthood 
 As hypothesized, adolescent d-amphetamine treatment did not increase cocaine 
abuse risk in adult rats, but was instead protective in SHR and WIS across several 
measures. Specifically, in adult SHR, adolescent d-amphetamine reduced cocaine intake 
and active lever responding during acquisition of cocaine self-administration, and 
modestly reduced cocaine cue reactivity on the first day of reinstatement testing. The 
effects of adolescent atomoxetine treatment were similar, except that atomoxetine 
reduced cocaine-seeking responses across the entire seven-day reinstatement test phase in 
adult SHR. In contrast, adolescent methylphenidate treatment augmented multiple aspects 
of cocaine abuse risk in SHR, as described in the preceding chapters (Baskin et al, 2015; 
Harvey et al, 2011; Jordan et al, 2014). These findings suggest that d-amphetamine is a 
viable alternative to methylphenidate for teenagers with ADHD who are initiating 
treatment.  
 Surprisingly, d-amphetamine had the most robust effects on cocaine abuse risk in 
adult WIS. In this outbred control strain, adolescent d-amphetamine treatment delayed 
acquisition of cocaine self-administration, and reduced cocaine intake as well as active 
lever responding under FR1 and PR schedules of reinforcement in adulthood. Downward 
shifts in cocaine dose-response functions reflect reductions in the efficacy and motivating 
influence of cocaine reinforcement (Piazza et al, 2000). Notably, these effects were 
observed months after d-amphetamine treatment had been discontinued. Although 
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adolescent methylphenidate did not alter FR1 or PR dose-response functions in adult 
WIS, it decreased the speed to acquire cocaine self-administration in this strain, similar to 
d-amphetamine (Harvey et al, 2011).  
 In contrast to the moderately beneficial effects of adolescent d-amphetamine in 
SHR and WIS, d-amphetamine treatment speeded acquisition of cocaine self-
administration in adult WKY. Interestingly, adolescent atomoxetine treatment also 
speeded acquisition of cocaine self-administration in adult WKY, whereas adolescent 
methylphenidate had no effect on cocaine abuse risk in this strain (Harvey et al, 2011; 
Somkuwar et al, 2013a). Fortunately, these medications did not alter any other aspects of 
cocaine abuse risk in WKY. The observations of altered cocaine abuse risk following 
adolescent d-amphetamine treatment in WKY and WIS further emphasize the necessity 
of assessing both inbred and outbred control strains when examining cocaine abuse risk 
in the SHR, as well as the importance of accurate diagnosis of ADHD. The implication of 
these findings, as well as the neurochemical mechanisms that may contribute to the 
effects of adolescent ADHD medications in these three strains, are explored in greater 
detail in Chapter Four. 
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CHAPTER FOUR. 
 
General Discussion 
 
 This dissertation sought to identify alternative medications to methylphenidate 
that would not increase cocaine abuse risk in newly diagnosed teenagers with ADHD, 
using a preclinical model. Experiments in Aim 1 focused on the effects of the non-
stimulant medication, atomoxetine, which inhibits NET function. Experiments in Aim 2 
focused on an alternative stimulant medication, d-amphetamine, which a different 
mechanism of action than methylphenidate. The significance of the findings is discussed 
in the subsequent sections.  
 
Importance of the Spontaneously Hypertensive Rat Model of ADHD 
 The results of this dissertation confirm and extend prior studies on cognitive 
functioning and cocaine abuse risk in the SHR model. For example, adolescent SHR 
exhibited deficits in behavioral flexibility during the set shift phase of the strategy set 
shifting task, consistent with prior studies (Harvey et al, 2013). Adolescent SHR also 
exhibited deficits in reaction time and reaction time variability during the initial set 
formation and reversal learning, compared to control strains. High reaction time 
variability is a novel finding in adolescent SHR, and is a well-reproduced feature of 
ADHD (Kofler et al, 2013). This finding thus further verifies the utility of adolescent 
SHR as a preclinical model of ADHD.  
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 During adulthood, SHR earned more cocaine infusions and made more active 
lever responses for cocaine than control strains throughout all experiments. More 
specifically, SHR acquired cocaine self-administration faster and were more sensitive to 
the efficacy and motivating influence of cocaine reinforcement, reflected in upward shifts 
in FR1 and PR cocaine dose-response functions, consistent with prior studies (Harvey et 
al, 2011). The novel finding of the current work regarding cocaine abuse risk is that SHR 
were more reactive to cocaine-related cues. High cue reactivity in SHR was found when 
cocaine was available (maintenance testing) and was not available (reinstatement testing 
and the first drug-free interval of maintenance testing) for self-administration. Moreover, 
the current work also demonstrated that SHR take longer to extinguish lever responding, 
consistent with observations in ADHD (Brackney et al, 2012; Kollins et al, 1997).  
 Sign tracking, a Pavlovian conditioned approach behavior associated with drug 
abuse (Tomie et al, 2008), may contribute to heightened incentive salience of cocaine-
associated cues in animals that are vulnerable to cocaine addiction, such as the SHR 
(Yager & Robinson, 2013). Whereas goal tracking involves approach to an unconditioned 
stimulus, sign tracking involves compulsive approach to reward-related cues. Although 
Pavlovian conditioned approach behavior has not been evaluated directly in SHR, 
ADHD-related characteristics, such as impulsivity and poor sustained attention, are 
observed in SHR as well as in sign tracking rats (Sagvolden et al, 2005; Tomie et al, 
2008; Wooters & Bardo, 2011). Thus, it is possible that SHR also have a sign tracking 
phenotype, given their high degree of cocaine cue reactivity. Although further studies on 
cocaine cue reactivity in ADHD are needed, if the current findings in SHR are 
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translational, substance-dependent individuals with ADHD may uniquely benefit from 
cue-exposure therapy (Mitchell et al, 2013), which seeks to extinguish the saliency of 
drug-related cues, and is most effective in individuals with initially high cue reactivity 
(Unrod et al, 2013). Moreover, pharmacotherapies that enhance extinction of drug-related 
cues by targeting glutamate signaling (Achat-Mendes et al, 2012; Kaplan et al, 2011) 
may have relevance for individuals with ADHD, who exhibit altered frontostriatal 
glutamate activity (Courvoisie et al, 2004; MacMaster et al, 2003). 
 In summary, this dissertation further confirms that value of the SHR as a model of 
comorbid ADHD and cocaine abuse risk. Given the increase in cocaine abuse risk 
conveyed by adolescent methylphenidate treatment in SHR (Baskin et al, 2015; Harvey et 
al, 2011; Jordan et al, 2014), it is important to identify other medications for teenagers 
with ADHD.  
 
Significance of Adolescent Atomoxetine Treatment on Cocaine Abuse Risk in Adulthood 
 Experiments 1 through 4 examined the effects of administration of a 
therapeutically relevant dose of atomoxetine during adolescence on cocaine abuse risk in 
adulthood. The results of these experiments demonstrate that, in contrast to 
methylphenidate, adolescent atomoxetine treatment does not increase cocaine abuse risk 
in adult SHR, and may even modestly reduce cocaine cue reactivity in this strain. The 
effects of adolescent atomoxetine treatment on monoamine transporter function and 
expression in PFC may help to explain these findings, as summarized in Tables 1 through 
3. For example, OFC activation plays a critical role in cocaine seeking and cue reactivity 
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(Di Pietro et al, 2008; Kantak et al, 2009; Nelissen et al, 2012). One past study 
demonstrated that daily atomoxetine (1 mg/kg) during late adolescence (P40 - 54) 
increased NET mRNA in the OFC of adult outbred rats (Sun et al, 2012). However, 
mRNA levels often do not correlate with protein expression (Greenbaum et al, 2003). A 
more recent study demonstrated that daily atomoxetine (3 mg/kg) during adolescence 
(P21 - 42) decreased NET protein levels in the hippocampus of outbred rats, for up to 2 
months after treatment was discontinued (Udvardi et al, 2013). Both studies inferred an 
inhibitory effect of atomoxetine on neural signaling: the 1 mg/kg treatment regimen 
decreased synaptic plasticity markers in the OFC, including BDNF mRNA and 
phosphorylated CREB and ERK (Sun et al, 2012), and the 3 mg/kg treatment regimen 
decreased glutamate NMDA receptor subunit levels in the hippocampus and striatum 
(Udvardi et al, 2013). While it remains to be determined if adolescent treatment with 0.3 
mg/kg atomoxetine decreases NET function or has an inhibitory effect on OFC in adult 
SHR, these mechanisms may contribute to the modest decrease in cocaine cue reactivity 
observed in adult SHR when cocaine was not available for self-administration. In 
addition, chronic treatment with 0.3 mg/kg of atomoxetine during adolescence decreases 
DAT function and expression in the OFC of adult SHR (Somkuwar et al, 2013a), which 
may also contribute to the reduction in cocaine cue reactivity. Atomoxetine treatment 
during adolescence similarly decreased DAT function in OFC of adult WIS (Somkuwar 
et al, 2013a), and in the current work did not alter any aspect of cocaine abuse risk in this 
strain. 
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 Another variable that may confer protection against an increase in cocaine abuse 
risk is the failure of adolescent atomoxetine to augment DAT function in the mPFC in 
adulthood (Somkuwar et al, 2013a). In previous studies, further increases in the speed to 
acquire cocaine self-administration, the efficacy and motivating influence of cocaine 
reinforcement, and cocaine intake was observed following discontinuation of adolescent 
methylphenidate vs. vehicle treatment in adult SHR (Harvey et al, 2011; Jordan et al, 
2014). The same adolescent methylphenidate treatment regimen also selectively 
increased DAT function in mPFC of adult SHR (Somkuwar et al, 2013b). As reviewed in 
Chapter One, an increase in mPFC DAT function may contribute to an enhanced 
reinforcing value of cocaine. Notably, in contrast to its effects on cocaine intake, 
adolescent methylphenidate treatment did not alter cocaine seeking during maintenance 
or reinstatement testing and did not alter the number of sessions required to reach the 
extinction criterion in adult SHR (Jordan et al, 2014). Because adolescent 
methylphenidate further increased cocaine intake in SHR, it might be expected that cue 
reactivity also would be further increased. However, these results were consistent with 
prior findings in outbred rats showing that acute administration of methylphenidate did 
not alter cocaine seeking under a second-order schedule (Economidou et al, 2011).  
 In summary, although additional work is needed to confirm the mechanisms and 
signaling pathways involved, the protective effect of atomoxetine against increases in 
cocaine abuse risk likely relates to long-lasting effects on NET and DAT function in 
OFC, and a lack of effect on DAT function in mPFC. These findings suggest that 
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adolescent atomoxetine treatment may represent a safer medication than methylphenidate 
for newly diagnosed teenagers with ADHD. 
 It is important to note that adolescent atomoxetine speeded acquisition of cocaine 
self-administration in the inbred WKY control strain. Consistent with the proposed role 
of DAT in cocaine abuse risk, adolescent atomoxetine treatment increases DAT function 
in OFC of WKY (Somkuwar et al, 2013a). This neurochemical adaptation may contribute 
to an enhanced reinforcing value of cocaine in WKY when cocaine first became available 
for self-administration, by increasing the post-synaptic response to phasically released 
dopamine under conditions of low dopaminergic tone (Grace, 2001). WKY exhibit 
several abnormalities in monoamine transporter activity that may be uniquely altered by 
adolescent medications, leading to differential effects on cocaine abuse risk. For example, 
compared to outbred rats, WKY show decreased DAT density in the nucleus accumbens 
(Jiao et al, 2003), but increased NET binding in the hippocampus and amygdala (Tenjani-
Butt et al, 1994). Moreover, compared to WIS, WKY exhibit reduced serotonin levels in 
several brain regions involved in cocaine abuse, including the amygdala, hypothalamus, 
nucleus accumbens, substantia nigra, and dorsal raphe nucleus (Scholl et al, 2010). Scholl 
and colleagues (2010) suggest that altered serotonin levels may reflect a reduction in 
serotonin transporters (SERT) sites in WKY. Importantly, SERT knockout speeds 
acquisition of psychostimulant self-administration and increases sensitivity to cocaine 
(Homberg et al, 2008; Oakly et al, 2014). Although atomoxetine is considered a selective 
NET inhibitor, evidence exists that this drug also binds to SERT (Ding et al, 2014). 
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Atomoxetine may therefore contribute to faster acquisition of cocaine self-administration 
in WKY, by exacerbating pre-existing SERT dysfunction in this strain.  
 While the results of Aim 1 do not critically call the into question the safety of 
adolescent atomoxetine, the impact of atomoxetine on cocaine abuse risk in the WKY 
control strain nonetheless has at least two important implications. One is that it is critical 
to evaluate both inbred and outbred control strains when examining the effects of 
adolescent medication in the SHR model of ADHD. In the current work, if WIS were the 
sole comparator strain, adolescent atomoxetine would appear to have few negative effects 
on cocaine abuse risk. Conversely, if WKY were the sole comparator strain to the SHR, 
adolescent atomoxetine may appear to be unsafe for teenagers without ADHD. In either 
case, with the use of only one control strain the consequences of adolescent atomoxetine 
on cocaine abuse risk would have been misrepresented.  
 The second implication of the results of Aim 1 is the critical importance of 
accurate diagnosis and treatment of ADHD. Because atomoxetine speeded acquisition of 
cocaine self-administration in WKY, misdiagnosis and subsequent treatment of ADHD in 
teenagers could result in a more rapid development of cocaine abuse. Unfortunately, there 
are currently no reliable biomarkers of ADHD that can be utilized in a clinical diagnosis. 
The development of strict diagnostic criteria and appropriate treatments for ADHD may 
have been hindered by skepticism surrounding ADHD as a neurological disorder in the 
international community (Heal et al, 2013). For example, ADHD has been criticized as an 
“American diagnosis,” and even today remains under-diagnosed and under-treated in the 
United Kingdom and other countries (Heal et al, 2013). This criticism is negated by the 
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many genetic and neurochemical abnormalities that are associated with ADHD, which 
have been reviewed extensively above. Future research must therefore work towards 
identifying more reliable biomarkers that can be used alongside behavioral and cognitive 
measures to refine clinical diagnoses.  
 
Significance of Adolescent d-Amphetamine Treatment on Cocaine Abuse Risk in 
Adulthood 
 While the results of Aim 1 suggest that atomoxetine may be a better treatment 
than methylphenidate for teenagers with ADHD, atomoxetine is not always as clinically 
efficacious as methylphenidate (Cubillo et al, 2014; Faraone et al, 2006; Sibley et al, 
2014). Moreover, atomoxetine modestly worsened adolescent SHR performance during 
the initial phase of the strategy set-shifting task, and had non-specific effects in control 
strains (see Table 1; Harvey et al, 2013). Adolescent atomoxetine also increased active 
lever responding during acquisition of cocaine self-administration and slowed extinction 
learning in adult SHR. These effects are not as alarming as those observed after 
adolescent methylphenidate treatment. Nonetheless, it would be useful to identify an 
alternative medication for teenagers with ADHD that is both efficacious and does not 
increase cocaine abuse risk. Therefore, experiments in Aim 2 investigated a different 
stimulant medication, d-amphetamine.  
 d-Amphetamine may be more efficacious in alleviating ADHD symptoms than 
atomoxetine and methylphenidate (Arnold, 2000; Faraone & Buitelaar, 2010; Patrick & 
Morowitz, 1997; Sibley et al, 2014). Although d-amphetamine inhibits DAT and NET 
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like methylphenidate, it is also taken up into the cell through monoamine transporters, 
where it blocks VMAT-2 and binds to TAAR1 (Easton et al, 2007). Because of these 
additional mechanisms of action, adolescent d-amphetamine was hypothesized to have 
different effects on prefrontal cortex function and cocaine abuse risk than 
methylphenidate. Consistent with this hypothesis, d-amphetamine improved behavioral 
flexibility in adolescent SHR in Experiment 5, an effect that was not observed with 
methylphenidate treatment. In children with ADHD, treatment with d-amphetamine, as 
well as other ADHD medications, normalized the abnormal striatal glutamate levels that 
may contribute to ADHD-related symptoms in both humans and SHR (Carrey et al, 2003; 
Courvoisie et al, 2004; MacMaster et al, 2003; Miller et al, 2014; Spencer et al, 2013; 
Warton et al, 2009). However, future work is needed to determine whether d-
amphetamine alters glutamate signaling in the striatum or substantia nigra of the SHR 
model.  
 In contrast to d-amphetamine, adolescent treatment with methylphenidate 
improved the speed of learning and choice accuracy in adolescent SHR only during the 
initial set formation phase (Harvey et al, 2013). The non-stimulant atomoxetine improved 
speed of learning and choice accuracy, and reduced trial omissions in the SHR during the 
set shift phase (Harvey et al, 2013), similar to the current observations with d-
amphetamine. The ability of d-amphetamine to improve behavioral flexibility in 
adolescent SHR may relate in part to its effects not only on glutamate, but also on NET 
and DAT function in PFC. Like atomoxetine, d-amphetamine augments noradrenergic 
signaling through inhibition and as well as reversal of NET, which can improve set 
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shifting performance (Cain et al, 2011; Easton et al, 2007; Lapiz & Morilak, 2006; 
McGaughy et al, 2008). Moreover, unlike methylphenidate, chronic treatment with d-
amphetamine during adolescence may decrease DAT expression and function in PFC due 
to amphetamine’s activity at VMAT-2 and TAAR1 (Miller, 2011; Xie & Miller, 2009). 
Interestingly, adolescent SHR, like cocaine users, exhibit lower levels of VMAT-2 
expression in the striatum compared to controls (Narendran et al, 2012; Simchon et al, 
2010), which may contribute to d-amphetamine’s unique effects in this strain. 
Nonetheless, reduced DAT expression and function after adolescent d-amphetamine 
treatment would result in slower clearance of dopamine and elevated dopaminergic tone 
in mesocortical neurons (Easton et al, 2007; Zahniser & Sorkin, 2004). Importantly, 
activation of post-synaptic D1 and D2 receptors in mPFC facilitates behavioral flexibility 
in outbred rats (Floresco, 2013; Floresco et al, 2006; Ragozzinno, 2002). Adolescent d-
amphetamine may therefore produce optimal activation at D1 and D2 receptors in mPFC 
of SHR, improving behavioral flexibility. Although the effect of d-amphetamine on 
mPFC DAT function is not confirmed, recently, acute amphetamine administration (0.56 
mg/kg, i.v.) was found to reduce DAT function and expression in nucleus accumbens of 
adult outbred rats (Ferris et al, 2015). However, additional studies are needed to test this 
hypothesis in mPFC of the SHR model, using a chronic dosing regimen of d-
amphetamine during adolescence that is clinically relevant to ADHD. In contrast, chronic 
treatment with methylphenidate during adolescence increases DAT function in mPFC of 
SHR (Somkuwar et al, 2013b). This action potentially exacerbates pre-existing elevations 
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of DAT in SHR (Mill et al, 2005; Watanabe et al, 1997; Zahniser & Sorkin, 2004), and 
may lead to reduced dopaminergic signaling in mPFC.  
 In addition to improving behavioral flexibility in adolescent SHR, Experiments 6 
through 9 revealed that adolescent d-amphetamine treatment does not increase cocaine 
abuse risk in adult SHR. Rather, adolescent d-amphetamine reduced cocaine intake 
during acquisition of self-administration, and, like atomoxetine, modestly decreased 
cocaine cue reactivity in adult SHR. As suggested above, the differential effects of 
adolescent d-amphetamine and methylphenidate on cocaine abuse risk in adulthood likely 
relate to their different long-term effects on monoamine transporter function in PFC (see 
Tables 1 through 3). For example, whereas adolescent methylphenidate increases mPFC 
DAT function and increases the reinforcing value of cocaine in SHR (Grace, 2001; 
Somkuwar et al, 2013b; Zahniser & Sorkin, 2004), adolescent atomoxetine and d-
amphetamine may decrease DAT function in adult SHR, and consequently reduce the 
reinforcing value of cocaine (Ferris et al, 2015; Somkuwar et al, 2013a; Zahniser & 
Sorkin, 2004). It is probable that additional neurochemical adaptations contribute to the 
long-term effects of d-amphetamine, such as changes in post-synaptic receptors or NET 
and SERT, to which amphetamine also potently binds and reverses transport (Easton et 
al, 2007; Heal et al, 2013; Heijtz et al, 2003). Moreover, in outbred rats, early adolescent 
treatment with a clinically relevant dose of amphetamine has been shown to increase 
dendritic length, dendritic branching, and calcium/calmodulin kinase II signaling in 
mPFC, suggesting enhanced frontostriatal dopamine-glutamate interactions (Heijtz et al, 
2003). Although future investigations are needed to determine the long-term 
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neurochemical effects of d-amphetamine in SHR, these findings nonetheless suggest that 
d-amphetamine is a viable alternative to methylphenidate for teenagers with ADHD who 
are initiating treatment.  
 The effects of adolescent d-amphetamine were even more profound in WIS. In 
this outbred control strain, adolescent d-amphetamine treatment slowed acquisition of 
cocaine self-administration and significantly reduced the efficacy and motivating 
influence of cocaine reinforcement, without influencing cognitive performance during 
adolescence. Interestingly, adolescent methylphenidate slowed acquisition speed in adult 
WIS, and decreased the affinity of DAT for dopamine in OFC of adult WIS (Somkuwar 
et al, 2013b). If adolescent d-amphetamine treatment has similar effects on reducing 
aspects of DAT function, as proposed above, this may contribute to the drug’s protective 
effects against cocaine abuse risk in adult WIS.  
 Taken together, these results suggest that d-amphetamine may be an even more 
valuable medication than methylphenidate or atomoxetine for teenagers with ADHD. 
While concern has been raised regarding the abuse liability of d-amphetamine as a 
prescription medication in itself, there is little actual abuse of d-amphetamine by ADHD 
patients (Heal et al, 2013). The pharmacokinetics of orally administered d-amphetamine 
make it significantly less reinforcing than cocaine or methamphetamine, and clinically 
relevant doses of d-amphetamine are unlikely to produce the euphoria associated with 
compulsive drug use (Heal et al, 2013). Moreover, the pro-drug, lisdexamphetamine 
(Vyvanse®), has recently been developed to further deter abuse, by requiring enzymatic 
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hydrolysis within red blood cells in order to be converted into the psychoactive d-
amphetamine metabolite (Heal et al, 2013; Pennick, 2010).  
 Interestingly, adolescent d-amphetamine, like atomoxetine, speeded acquisition of 
cocaine self-administration in adult WKY. As reviewed above, WKY exhibit a number of 
behavioral and neurochemical abnormalities that may be reminiscent of a 
depressive/anxiety-prone phenotype (Cominski et al, 2014; De La Garza II & Mahoney 
III, 2004; Jiao et al, 2003; Pardon et al, 2002; Paré et al, 2002; Novick et al, 2008; Scholl 
et al, 2010). The effects of adolescent d-amphetamine in WKY may relate to unique 
alterations in DAT and SERT function in this strain (see Tables 2 and 3; Jiao et al, 2003; 
Tenjani-Butt et al, 1994; Scholl et al, 2010). If the neurochemical effects of d-
amphetamine resemble those of atomoxetine, d-amphetamine may produce increases in 
DAT function in PFC of adult WKY, thereby augmenting the reinforcing value of 
cocaine (Grace, 2001; Somkuwar et al, 2013a). However, the mechanism by which d-
amphetamine may exert this effect on DAT in WKY is unclear. Amphetamines are also 
known to reduce SERT function in the striatum of outbred rats (Haughey et al, 2000; 
Kokoshka et al, 1998). If d-amphetamine reduces SERT function in WKY, faster 
acquisition of cocaine self-administration following adolescent d-amphetamine treatment 
may reflect an exacerbation of pre-existing reductions in SERT in this strain (Homberg et 
al, 2008; Oakly et al, 2014; Scholl et al, 2010). However, the effects of adolescent 
treatment with clinically relevant doses of d-amphetamine on SERT function in adult 
WKY have yet to be evaluated. Nonetheless, in conjunction with the results of Aim 1, 
findings in WKY emphasize the necessity of evaluating both inbred and outbred control 
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strains alongside the SHR. Moreover, the effects of d-amphetamine in control strains 
further highlight the importance of accurate diagnosis and treatment of ADHD. The long-
term consequences of misdiagnosis and subsequent treatment could be favorable (d-
amphetamine in WIS) or unfavorable (atomoxetine and d-amphetamine in WKY) in 
misdiagnosed individuals.   
 
Treatment and Prevention of Cocaine Abuse 
 Interestingly, amphetamines have shown efficacy in the treatment of cocaine use 
disorders. In outbred rats with cocaine self-administration experience, d-amphetamine 
produces downward shifts in PR cocaine dose-response functions (Chiodo et al, 2008; 
Zimmer et al, 2014), and reverses cocaine-induced deficits in DAT expression and 
function (Ferris et al, 2015). In non-human primates, d-amphetamine also reduces 
cocaine self-administration under PR and second-order schedules of reinforcement, and 
increases choice for food over cocaine (Czoty et al, 2010; Grabowski et al, 2004; Negus, 
2003; Negus & Mello, 2003a, b). Moreover, in cocaine-abusing subjects, moderate doses 
of amphetamine reduce cocaine intake and craving, and improve treatment retention 
(Grabowski et al, 2001, 2004; Mooney et al, 2009). In individuals with ADHD and 
comorbid cocaine use disorder, amphetamine is effective both in reducing cocaine use 
and in improving ADHD symptoms (Levin et al, 2015).  In contrast, methylphenidate is 
not effective in stimulant-dependent ADHD patients, possibly because of limited efficacy 
at DAT due to cocaine’s long-term effects (Crunelle et al, 2013; Grabowski et al, 2004; 
Konstenius et al, 2010).  
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 Many other treatments for cocaine use disorders have been investigated, including 
the administration of other DAT, NET, and SERT inhibitors and monoamine agonists, as 
well as monoamine antagonists and anti-cocaine vaccines (Grabowski et al, 2004; Howell 
& Negus, 2014; Kinsey et al, 2010). However, all have been met with limited efficacy. 
There is currently no “cure” for cocaine use disorder. Recently, preventative measures, 
particularly for adolescents, have received attention as potentially more effective ways to 
reduce the prevalence of cocaine use disorder (e.g., Stanis & Andersen, 2014). The 
current work is the first to demonstrate that adolescent treatment with d-amphetamine 
may reduce later cocaine abuse risk in outbred rats. Therefore, d-amphetamine treatment 
may be a viable preventative measure in at-risk teenage populations. The understanding 
of the neural mechanisms contributing to this protective effect, set forth in this 
dissertation, may lead to other targeted leads in the treatment of ADHD and prevention of 
cocaine abuse.  
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 Future Directions  
 The results of the current work raise numerous questions for future investigation, 
particularly regarding the neural mechanisms underlying the effects of atomoxetine and 
d-amphetamine in SHR, WIS, and WKY. Another important direction for future research 
is to investigate the long-term effects of ADHD medications in females with ADHD. 
Women with ADHD may have a higher risk of substance use than men with ADHD 
(Dalsgaard et al, 2014). Moreover, women tend to progress from recreational drug use to 
drug dependence faster than men, and have higher relapse rates (Bobzean et al, 2014). 
Although ADHD is more common in males during childhood, by adulthood the ratio of 
males to females diagnosed with ADHD is nearly 1:1 (Barkley et al, 2011; Collingwood, 
2010). This may be due to higher rates of self-referral by women in adulthood, or because 
girls are more likely to exhibit the inattentive subtype of ADHD and remain undiagnosed 
until adolescence or adulthood (Collingwood, 2010). Women with ADHD tend to exhibit 
more perseverative and internalizing symptoms than men, while men exhibit more 
Monoamine 
Tranporter
Level of   
Function
Behavioral 
Flexibility in 
Adolescence
Cocaine Abuse 
Risk in 
Adulthood
High - Increases
Low Improves Decreases
High - -
Low Improves Decreases
High - -
Low - Increases
DAT
NET
SERT
Table 3: Proposed Role of Monoamine Tranporters in Behavior
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impulsive, hyperactive, and motivational symptoms (Collingwood, 2010; Nussbaum et al, 
2012). Women with ADHD are also more likely to develop comorbid anxiety and 
depressive conditions than men (Collingwood, 2010), and more variable responses to 
ADHD medication (Nussbaum et al, 2012).  
 Despite these observations, the effects of stimulant and non-stimulant ADHD 
medications on cognition and cocaine abuse risk in females are not well known. The SHR 
may be a valuable starting point in advancing understanding of ADHD comorbidities in 
females. Similar to the gender differences observed in individuals with ADHD, female 
SHR exhibit more inattentive and perseverative traits, whereas male SHR exhibit more 
hyperactivity and impulsivity (Berger & Sagvolden, 1998). Consistent with suggestions 
that woman with ADHD have higher substance use risk than men, female SHR showed 
greater sensitization to cocaine and exhibited higher ethanol intake than male SHR 
(Cailhol & Mormède, 1999; Vendruscolo et al, 2009). In addition, female SHR were 
more vulnerable to the effects of adolescent methylphenidate treatment on increasing 
ethanol intake than male SHR (Vendruscolo et al, 2008). Future studies can therefore 
begin to address the effects of ADHD medication in females with ADHD using the SHR 
model.  
 
Limitations 
  There are limitations to every animal model of human disease, and the SHR has 
not been exempt from criticism. For example, while some studies have observed 
hyperactivity in the SHR during open field tests, others have shown that SHR 
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hyperactivity is dependent upon specific task parameters and the control strains that are 
employed (Ferguson & Cada, 2003; Sagvolden et al, 1992; van den Bergh et al, 2006; 
Wickens et al, 2011). Notably, the open field test may have little relevance to ADHD, as 
locomotor activity of children in a playroom did not correlate with hyperactivity ratings 
or diagnosis (Routh & Schroeder, 1976; Schroeder et al, 1980; Wickens et al, 2011). 
Other work has questioned the predictive validity of the SHR model (van den Bergh et al, 
2006; Wickens et al, 2011). One study found that oral methylphenidate (0.1, 1.0, and 10 
mg/kg) did not reduce hyperactivity or impulsivity in the SHR (van den Bergh et al, 
2006). However, in this latter study methylphenidate was administered one hour prior to 
behavioral testing (van den Bergh et al, 2006). Previous work has shown that 
monoaminergic responses to oral methylphenidate (1.0, 2.5, and 5.0 mg/kg) peak 
approximately 30 minutes after administration (Kuczenski & Segal, 2002). Thus, 
monoamine levels may have already peaked if testing occurs 60 minutes after 
methylphenidate treatment, potentially obscuring any methylphenidate-induced 
improvements in behavior. Another study found that 3 mg/kg i.p. methylphenidate did 
not reduce impulsivity in SHR (Bizot et al, 2007). However, this i.p. dose of 
methylphenidate exceeds clinical relevance, producing elevations in nucleus accumbens 
dopamine that may be more reminiscent of a drug of abuse (Kuczenski & Segal, 2001). 
Studies utilizing clinically relevant dosing and treatment regimens (e.g., 1.5 mg/kg orally, 
30 minutes prior to behavioral testing) have shown that methylphenidate improves 
cognitive deficits in the SHR (Harvey et al, 2011; 2013; Kantak et al, 2008). Therefore, 
rather than questioning the predictive validity of the SHR, together these findings 
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highlight the importance of experimental designs that are clinically relevant to ADHD, 
particularly when evaluating ADHD medications.  
 There are limitations to the current experiments that are worthy of separate 
comment. For example, a small number of rats expired prior to completing all phases of 
the experiments within each Aim. Importantly, in all cases death was not caused by 
experimental factors, but rather to illness (n = 15), accidental overdose related to 
equipment malfunction (n = 4), or malfunction of temperature controls in the animal 
facility (n = 2). However, because experimental phases were not directly compared in the 
statistical analyses (e.g., cocaine intake in Experiment 2 was not compared to cocaine 
intake in Experiment 1), rat loss had a minimal impact on the current results and their 
interpretation.  
 Another limitation of these experiments is that some trend-level ANOVA effects 
(e.g., p ≤ 0.07) are reported, e.g., following strain X treatment interactions. However, in 
cases where trends are reported, post-hoc tests are statistically significant (p ≤ 0.05), 
suggesting that these behavioral differences are reliable. One final notable limitation of 
the current experiments is the use of single doses of atomoxetine and d-amphetamine in 
the adolescent treatment regimens. Although assessment of multiple of doses may help to 
elucidate potential dose-related effects of these ADHD medications on cocaine abuse 
risk, the doses employed in the current work were carefully selected to be clinically 
relevant using evidence from prior studies. For example, the 0.3 mg/kg atomoxetine dose 
was chosen because this dose primarily increases extracellular norepinephrine, and to a 
lesser extent dopamine, in PFC (Bymaster et al, 2002). Higher doses (e.g., 3 mg/kg 
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atomoxetine), in contrast, have greater effects on extracellular dopamine (Bymaster et al, 
2002), which may lead to non-specific behavioral effects. Moreover, the 0.3 mg/kg dose 
of atomoxetine has been shown to improve behavioral flexibility in adolescent SHR 
(Harvey et al, 2013). With respect to d-amphetamine, when administered s.c., 0.5 mg/kg 
amphetamine produces plasma drug concentrations of 84 ± 4 ng/mL in the rat (Heijtz et 
al, 2003). In patients with ADHD, d-amphetamine may be prescribed at doses ranging 
from 0.2 - 0.6 mg/kg/day, which produce peak plasma levels ranging from 64 - 84 ng/mL 
(Brown et al, 1979; Bymaster et al, 2002). Thus, doses higher than 0.5 mg/kg d-
amphetamine may produce plasma concentrations that exceed clinical relevance (Heijtz 
et al, 2003). Although the pharmacokinetcs of s.c. and i.p. routes of administration (the 
latter of which was used in the current studies) may differ, both routes produce similar 
plasma levels and time-concentration curves following low-dose psychostimulant 
administration (Baumann et al, 2009).  Moreover, in the rat 0.5 mg/kg d-amphetamine 
(s.c. or i.p.) does not induce locomotor activation, and increases dopamine and 
norepinephrine activity as well as dendritic growth in PFC (Brown et al, 1979; Heitjz et 
al, 2003; Labonte et al, 2011). Because 0.5 mg/kg d-amphetamine did not alleviate all 
ADHD-related deficits in adolescent SHR, and produced modest protective affects 
against cocaine abuse risk in adult SHR in the current work, it seems unlikely that 
investigations of lower doses of d-amphetamine would produce significant behavioral 
findings. Rather, these observations indicate that the current work employs doses that are 
representative of and relevant to those used in clinical settings. Nonetheless, future 
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research may benefit from investigation of the effects of adolescent treatment with 
alternative doses of atomoxetine and d-amphetamine.  
 
 
Conclusions 
 Questions regarding the long-term effects of adolescent ADHD medication on 
later substance use disorders, and particularly cocaine abuse risk, have been historically 
difficult to examine in a systematic manner. Preclinical models have promise in 
addressing gaps in the clinical literature. In particular, the SHR exhibits behavioral and 
cognitive deficits, as well as neurochemical and genetic differences, reflecting those 
observed in ADHD. The results of this dissertation, together with previous work, indicate 
that the SHR has important heuristic value in modeling aspects of cognitive dysfunction, 
cocaine abuse risk, and cocaine cue reactivity. Moreover, the SHR is an important model 
for assessing the neurobiology underlying the ADHD phenotype, and for evaluating 
pharmacotherapeutics for teenagers with ADHD.  
 Illicit drug use costs the United States over $193 billion each year (NIDA, 2015).  
Nearly two-thirds of treatment-seeking drug users report sampling drugs before age 20 
(SAMHSA, 2002; Stanis & Andersen, 2014). Moreover, initiating drug use before age 14 
is associated with four times the likelihood of becoming drug dependent in adulthood 
(SAMHSA, 2006; Stanis & Andersen, 2014). With approximately 1,600 teens and adults 
initiating cocaine use each day (SAMHSA, 2013), it becomes critically important to 
reduce the risk of cocaine abuse, particularly in vulnerable populations. This dissertation 
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presents novel findings, using an animal model, on the potential consequences of ADHD 
medication in humans. Specifically, atomoxetine and d-amphetamine may be safer 
medications than the more commonly prescribed methylphenidate for newly diagnosed 
teenagers with ADHD. Application of the current preclinical findings to a clinical setting 
could effectively minimize the risk of SUD in an estimated ~700,000 teenagers with 
ADHD, who may be receiving medication for the first time (NSCH Database, 2011). 
Moreover, applying an understanding of the long-term neurochemical effects of drugs of 
the same class, such as stimulants, to a clinical setting could lead to more appropriate 
treatments for ADHD.  
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